[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1545
1. Karrman K, Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Ehrencrona H, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Palmqvist L, Johansson B, Nordic Society of Pediatric Hematology, Oncology (NOPHO), Swedish Cytogenetic Leukemia Study Group (SCLSG), NOPHO Leukemia Cytogenetic Study Group (NLCSG): Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes Cancer; 2009 Sep;48(9):795-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome.
  • Clinical characteristics and cytogenetic aberrations were ascertained and reviewed in a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias (T-ALLs) diagnosed between 1992 and 2006 in the Nordic countries.
  • The most frequent abnormalities were T-cell receptor (TCR) gene rearrangements (20%) [TCR;11p13 (10%), TCR;10q24 (3%), TCR;other (8%)], del(9p) (17%), +8 (14%), del(6q) (12%), and 11q23 rearrangements (6%).
  • The clinical characteristics of this Nordic patient cohort agreed well with previous larger series, with a median age of 9.0 years, male predominance (male/female ratio 3.1), median white blood cell (WBC) count of 66.5 x 10(9)/l, and a high incidence of mediastinal mass and central nervous system involvement (59% and 9.5%, respectively).
  • In conclusion, in this large series of childhood T-ALLs from the Nordic countries, the cytogenetic findings were not associated with risk of therapy failure with the exception of the TCR;other group.
  • [MeSH-major] Chromosome Aberrations. Gene Rearrangement, T-Lymphocyte. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530250.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


2. Masserot C, Adjaoud D, Haouy S, Deswarte C, Ballerini P, Landman-Parker J: Acute lymphoblastic leukemia and cutaneous mastocytosis in two children. Pediatr Blood Cancer; 2008 Sep;51(3):444-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia and cutaneous mastocytosis in two children.
  • [MeSH-major] Mastocytosis, Cutaneous / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology


3. Hassan R, White LR, Stefanoff CG, de Oliveira DE, Felisbino FE, Klumb CE, Bacchi CE, Seuánez HN, Zalcberg IR: Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol; 2006 Aug 07;1:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a systematic comparison between RISH and PCR for EBV detection, in a group of childhood B-cell Non-Hodgkin lymphomas (NHL), aiming to validate PCR as a first, rapid method for the diagnosis of EBV-associated B-cell NHL.
  • METHODS: EBV infection was investigated in formalin fixed paraffin-embedded tumor samples of 41 children with B-cell NHL, including 35 Burkitt's lymphoma (BL), from Rio de Janeiro, Brazil, by in situ hybridization of EBV-encoded small RNA (EBER-RISH) and PCR assays based on EBNA2 amplification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 Aug;141(2):457-65 [1323222.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1572-5 [15284857.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] Cell. 1988 Jan 15;52(1):51-61 [2830981.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] J Virol. 1994 Nov;68(11):7374-85 [7933121.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):604-11 [7967515.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):239-52 [8053485.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Pediatr Pathol. 1994 Jan-Feb;14(1):101-9 [8159607.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):36-42 [8381202.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1045-55 [8562929.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] J Virol. 1996 May;70(5):3286-9 [8627812.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1245-52 [8630905.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3949-55 [10339504.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):79-87 [12766612.001]
  • [Cites] J Clin Microbiol. 1999 Sep;37(9):2852-7 [10449464.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):331-5 [11860309.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):329-37 [11342313.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53 [10781747.001]
  • [Cites] Arch Pathol Lab Med. 1999 Nov;123(11):1098-100 [10539915.001]
  • (PMID = 16893464.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082274
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1559641
  •  go-up   go-down


Advertisement
4. Matherly LH, Hou Z, Deng Y: Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev; 2007 Mar;26(1):111-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since RFC was first cloned in 1994, tremendous advances have been made in understanding the complex transcriptional and posttranscriptional regulation of RFC, in identifying structurally and functionally important domains and amino acids in the RFC molecule as a prelude to establishing the mechanism of transport, and in characterizing the molecular defects in RFC associated with loss of transport in antifolate resistant cell line models.
  • Many of the advances in the basic biology of RFC in cell line models are now being directly applied to human cancers in the clinical setting, most notably pediatric acute lymphoblastic leukemia and osteogenic sarcoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334909.001).
  • [ISSN] 0167-7659
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA53535; United States / NCI NIH HHS / CA / CA76641
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Membrane Transport Proteins; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; 935E97BOY8 / Folic Acid
  • [Number-of-references] 165
  •  go-up   go-down


6. van Beek RD, Bezemer DD, Meijerink JP, de Muinck Keizer-Schrama SM, Haas OA, Te Winkel L, Pieters R, van den Heuvel-Eibrink M: Repeats in the kringle IV encoding domains in the Apo(a) gene and serum lipoprotein(a) level do not contribute to the risk for avascular necrosis of the bone (AVN) in pediatric acute lymphoblastic leukemia. Leukemia; 2006 May;20(5):879-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeats in the kringle IV encoding domains in the Apo(a) gene and serum lipoprotein(a) level do not contribute to the risk for avascular necrosis of the bone (AVN) in pediatric acute lymphoblastic leukemia.
  • [MeSH-major] Apolipoproteins A / genetics. Kringles / genetics. Lipoprotein(a) / blood. Osteonecrosis / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525499.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apolipoproteins A; 0 / Lipoprotein(a)
  •  go-up   go-down


7. Franklin JL, Seibel NL, Krailo M, Fu C, Adamson PC, Reaman G, Children's Oncology Group: Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report. Pediatr Blood Cancer; 2008 Mar;50(3):533-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report.
  • BACKGROUND: To determine the response rate and toxicity of docetaxel when administered as a 60 mg/m(2) dose by 1 hr intravenous (IV) infusion weekly x 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Leukemia / drug therapy. Salvage Therapy. Taxoids / therapeutic use
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Bone Marrow Diseases / chemically induced. Child. Child, Preschool. Drug Administration Schedule. Female. Fever / etiology. Humans. Infant. Infusions, Intravenous. Leukemia, Myeloid / drug therapy. Male. Neutropenia / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17668867.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


8. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE, Friedman DL: Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant; 2010 Dec;16(12):1674-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation.
  • Survivors of childhood acute lymphoblastic leukemia (ALL) may face an increased risk of metabolic and cardiovascular late effects.
  • To determine the prevalence of and risk factors for adverse cardiometabolic traits in a contemporary cohort of pediatric ALL survivors, we recruited 48 off-therapy patients in remission treated with conventional chemotherapy and 26 treated with total body irradiation (TBI)-based hematopoietic cell transplantation (HCT) in this cross-sectional pilot study.
  • In summary, pediatric ALL survivors exposed to TBI-based HCT as well as to any cranial radiation may manifest cardiometabolic traits at an early age and should be screened accordingly.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1521-5 [15585763.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] Circulation. 2006 Apr 18;113(15):1888-904 [16618833.001]
  • [Cites] Diabet Med. 2006 May;23(5):469-80 [16681555.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1109-17 [16699534.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4401-7 [16954158.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] Cardiovasc Res. 2007 Apr 1;74(1):11-8 [17140553.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):529-34 [17762493.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3816-21 [17652222.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3463-71 [17664354.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):160-4 [18206681.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):177-84 [18206686.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):185-90 [18206687.001]
  • [Cites] Diabetes Metab. 2008 Feb;34(1):2-11 [18093861.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):319-42, viii [18395153.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):797-804 [18195686.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Jun;21(2):129-38 [18503981.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):11-26 [18430191.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Nov;69(5):819-27 [18429947.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):815-22 [18989158.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5537-43 [18809605.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(1):49-54 [18724397.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3698-704 [19564534.001]
  • [Cites] PLoS Genet. 2009 Dec;5(12):e1000768 [20011104.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):170-81 [20056636.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):515-24 [19961945.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):993-7 [11041401.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Nutr. 2001 Aug;131(8):2184-91 [11481415.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):427-36 [12588201.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7 [12912790.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):81-90 [14767193.001]
  • [Cites] Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 [15286277.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] J Pediatr. 2004 Oct;145(4):439-44 [15480363.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Can J Public Health. 1986 Sep-Oct;77(5):359-62 [3791117.001]
  • [Cites] Am J Epidemiol. 1996 Jun 15;143(12):1219-28 [8651220.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1650-6 [9614255.001]
  • [Cites] Transplantation. 2004 Nov 15;78(9):1376-83 [15548978.001]
  • (PMID = 20685399.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024975-01; United States / NCRR NIH HHS / RR / UL1 RR025014-01; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCRR NIH HHS / RR / KL2 RR024977; None / None / / UL1 RR025014-01; United States / NCRR NIH HHS / RR / UL1RR025014; United States / NCRR NIH HHS / RR / UL1RR024975; United States / NCRR NIH HHS / RR / UL1 RR025014; United States / NCRR NIH HHS / RR / UL1 RR024975
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS211258; NLM/ PMC2975816
  •  go-up   go-down


9. Li Z, Zhang W, Wu M, Zhu S, Gao C, Sun L, Zhang R, Qiao N, Xue H, Hu Y, Bao S, Zheng H, Han JD: Gene expression-based classification and regulatory networks of pediatric acute lymphoblastic leukemia. Blood; 2009 Nov 12;114(20):4486-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression-based classification and regulatory networks of pediatric acute lymphoblastic leukemia.
  • Pediatric acute lymphoblastic leukemia (ALL) contains cytogenetically distinct subtypes that respond differently to cytotoxic drugs.
  • [MeSH-major] Gene Expression Profiling / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755675.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A: PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet; 2010 Apr;42(4):338-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PHF6 mutations in T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with an increased incidence in males.
  • In this study, we report the identification of inactivating mutations and deletions in the X-linked plant homeodomain finger 6 (PHF6) gene in 16% of pediatric and 38% of adult primary T-ALL samples.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14440-4 [10588724.001]
  • [Cites] Blood. 2009 Dec 10;114(25):5136-45 [19828704.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):661-5 [12415272.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Clin Genet. 2004 Mar;65(3):226-32 [14756673.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7364-9 [10377420.001]
  • [Cites] Acta Med Scand. 1962 Jan;171:13-21 [13871358.001]
  • [Cites] Curr Biol. 2005 Feb 8;15(3):R99-R102 [15694301.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):400-4 [15772666.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1283-98 [16564017.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1212-21 [16956820.001]
  • [Cites] Cytogenet Genome Res. 2006;115(3-4):247-53 [17124407.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Science. 2007 May 25;316(5828):1160-6 [17525332.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Gene Expr Patterns. 2007 Oct;7(8):858-71 [17698420.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):380-90 [18421304.001]
  • [Cites] Blood. 2008 May 1;111(9):4668-80 [18299449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7 [18669648.001]
  • [Cites] Annu Rev Genet. 2008;42:733-72 [18729722.001]
  • [Cites] Mutat Res. 2008 Dec 1;647(1-2):3-12 [18682256.001]
  • [Cites] Nat Biotechnol. 2009 Feb;27(2):182-9 [19182786.001]
  • [Cites] J Exp Med. 2009 Apr 13;206(4):779-91 [19349467.001]
  • [Cites] PLoS Comput Biol. 2009 May;5(5):e1000386 [19461883.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • (PMID = 20228800.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120196-03; United States / NIAID NIH HHS / AI / U54-AI057158; United States / NCI NIH HHS / CA / R01 CA129382; United States / NCI NIH HHS / CA / R01 CA129382-03; United States / NCI NIH HHS / CA / CA129382-03; United States / NCI NIH HHS / CA / CA120196-03; United States / NCI NIH HHS / CA / R01CA120196; United States / NIAID NIH HHS / AI / U54 AI057158; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / R01 CA120196; United States / NLM NIH HHS / LM / 1R01LM010140-01; United States / NCI NIH HHS / CA / U24 CA114737; United States / NLM NIH HHS / LM / R01 LM010140; United States / NCI NIH HHS / CA / R01 CA155743
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Homeodomain Proteins; 0 / PHF6 protein, human; 0 / Proto-Oncogene Proteins; 0 / TLX3 protein, human; 143275-75-6 / TLX1 protein, human
  • [Other-IDs] NLM/ NIHMS176587; NLM/ PMC2847364
  •  go-up   go-down


11. Sorich MJ, Pottier N, Pei D, Yang W, Kager L, Stocco G, Cheng C, Panetta JC, Pui CH, Relling MV, Cheok MH, Evans WE: In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med; 2008 Apr 15;5(4):e83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
  • BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients.
  • Although MTX has been extensively studied for many years, relatively little is known about mechanisms of de novo resistance in primary cancer cells, including leukemia cells.
  • METHODS AND FINDINGS: We utilized measures of decreased circulating leukemia cells of 293 newly diagnosed children after initial "up-front" in vivo MTX treatment (1 g/m(2)) to elucidate interpatient differences in the antileukemic effects of MTX.
  • We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating leukemia cells after initial in vivo treatment with MTX.
  • CONCLUSIONS: Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL.
  • TRIAL REGISTRATIONS: Total XV, Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia, http://www.ClinicalTrials.gov (NCT00137111); Total XIIIBH, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Intermediate or High Risk of Treatment Failure (NCI-T93-0101D); Total XIIIBL, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Lower Risk of Treatment Failure (NCI-T93-0103D).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Profiling. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):93-9 [14693814.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95 [12972803.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Vitam Horm. 2003;66:403-56 [12852262.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):775-81 [12618889.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1240-7 [12149204.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2423-9 [12114448.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1832-9 [16936229.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Biochem Pharmacol. 1999 Aug 15;58(4):539-55 [10413291.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1067-74 [9920857.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5638-44 [2458828.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1449-63 [2207320.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1041-8 [8793930.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 18;88(18):1255-6 [8797761.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):20-4 [9915496.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Haematologica. 2001 Feb;86(2):121-7 [11224479.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • (PMID = 18416598.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00137111
  • [Grant] United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R01 CA51001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2292747
  •  go-up   go-down


12. Sanford SD, Okuma JO, Pan J, Srivastava DK, West N, Farr L, Hinds PS: Gender differences in sleep, fatigue, and daytime activity in a pediatric oncology sample receiving dexamethasone. J Pediatr Psychol; 2008 Apr;33(3):298-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in sleep, fatigue, and daytime activity in a pediatric oncology sample receiving dexamethasone.
  • OBJECTIVE: To examine gender differences in sleep, fatigue, and daytime activity in a sample of children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Dexamethasone / therapeutic use. Fatigue / epidemiology. Motor Activity. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Sleep Wake Disorders / epidemiology

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024981.001).
  • [ISSN] 0146-8693
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765; United States / NINR NIH HHS / NR / R01 NR07610
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


13. Turial S, Karabul N, Gutjahr P, Engel V, Bierschock S, Schier F: Ovarian tumours: late extramedullary recurrence of acute leukaemia. Eur J Pediatr Surg; 2009 Jun;19(3):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumours: late extramedullary recurrence of acute leukaemia.
  • OBJECTIVE: Isolated extramedullary relapse, especially ovarian recurrence, of acute leukaemia is rare.
  • MATERIALS AND METHODS: Over a 20-year period we observed two girls with ovarian relapse of acute lymphoblastic leukaemia (ALL) in over 300 treated children for ALL.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212934.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Kulkarni KP, Marwaha RK, Trehan A, Bansal D: Testicular relapse in childhood acute lymphoblastic leukemia: the challenges and lessons. Indian J Cancer; 2010 Apr-Jun;47(2):134-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular relapse in childhood acute lymphoblastic leukemia: the challenges and lessons.
  • BACKGROUND: Relapse of disease is documented in 15-20% of children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Testicular Neoplasms / therapy


15. Paananen P, Arola MO, Pelliniemi TT, Salmi TT, Lähteenmäki PM: Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Oct;31(10):745-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia.
  • Differences in the triggering levels for red blood cell (RBC) and platelet (PLT) transfusions were analyzed in association to the amount and total costs of transfusions and the number of febrile episodes during childhood acute lymphoblastic leukemia (ALL) treatment.
  • Clinical trials are, however, necessary to determine optimal criteria for supportive blood transfusions in childhood cancer patients.
  • [MeSH-major] Blood Transfusion / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


16. Liang DC, Shih LY, Yang CP, Hung IJ, Liu HC, Jaing TH, Yeh TC, Liang ST, Chang CL, Lee EH, Lai CL, Chang WH: Frequencies of ETV6-RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west. Pediatr Blood Cancer; 2010 Sep;55(3):430-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequencies of ETV6-RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west.
  • BACKGROUND: Both ETV6-RUNX1 (TEL-AML1) fusion and hyperdiploidy (>50 chromosomes) in transformed lymphoblasts are favorable genetic features in childhood acute lymphoblastic leukemia (ALL).
  • These frequencies were lower than those reported in the West, leading us to conduct a meta-analysis of ETV6-RUNX1 fusion and hyperdiploidy frequencies in childhood ALL based on published reports.
  • CONCLUSIONS: This meta-analysis demonstrates lower frequencies of ETV6-RUNX1 fusion and hyperdiploidy among leukemia patients in the Far East compared with the West.
  • The integral relationship of these genetic features with a favorable outcome in childhood ALL warrants further study of potentially important epidemiologic factors, including placental exposure to leukemogenic agents, and host pharmacogenetics.
  • [MeSH-major] Diploidy. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658612.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


17. Bernaldez-Rios R, Ortega-Alvarez MC, Perez-Saldivar ML, Alatoma-Medina NE, Del Campo-Martinez Mde L, Rodriguez-Zepeda Mdel C, Montero-Ponce I, Franco-Ornelas S, Fernandez-Castillo G, Nuñez-Villegas NN, Taboada-Flores MA, Flores-Lujano J, Argüelles-Sanchez ME, Juarez-Ocaña S, Fajardo-Gutierrez A, Mejia-Arangure JM: The age incidence of childhood B-cell precursor acute lymphoblastic leukemia in Mexico City. J Pediatr Hematol Oncol; 2008 Mar;30(3):199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The age incidence of childhood B-cell precursor acute lymphoblastic leukemia in Mexico City.
  • The objective of this population-based survey was to assess the peak age of incidence of B-cell precursor acute lymphoblastic leukemia (ALL) in children in Mexico City (MC).
  • All patients were classified according to their immunophenotype, and only B-cell precursor and T-lineage were analyzed.
  • The frequency of B-cell precursor ALL was 76.1%, whereas T lineage ALL showed a frequency of 23.6%.
  • B-cell precursor ALL was the major contributor to peak age; T lineage ALL showed a peak among 1 and 3 years of age.
  • We conclude that the age peak for children with ALL in MC is within the ranges reported for developed countries and that B-cell precursor ALL is the main contributor to these peak.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


18. Gurney JG, Donohue JE, Ness KK, O'Leary M, Glasser SP, Baker KS: Health knowledge about symptoms of heart attack and stroke in adult survivors of childhood acute lymphoblastic leukemia. Ann Epidemiol; 2007 Oct;17(10):778-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health knowledge about symptoms of heart attack and stroke in adult survivors of childhood acute lymphoblastic leukemia.
  • PURPOSE: Children with acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, have a 5-year survival rate of better than 80%.
  • Long-term survivors of childhood ALL, however, carry an elevated risk of early mortality from cardiac events and stroke and a disproportionately high prevalence of dyslipidemia and obesity, presumably as an adverse effect of treatment.
  • METHODS: As part of a clinical follow-up study of 70 young adult survivors of childhood ALL, we evaluated the degree to which this high-risk group differed in knowledge about symptoms of heart attack and stroke from that of a population-based comparison group frequency-matched by age, sex, and body mass index.
  • CONCLUSIONS: These results indicate an important gap in knowledge and underscore the need for health education among survivors of childhood leukemia that includes information about symptoms of myocardial infarction and stroke.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Stroke. 2001 Jan;32(1):63-9 [11136916.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Cancer Treat Rev. 2002 Aug;28(4):195-214 [12363460.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3494S-3503S [12421876.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 May 7;53(17):359-62 [15129192.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):532-41 [8697401.001]
  • [Cites] Ann Med. 1997 Oct;29(5):353-5 [9453278.001]
  • [Cites] Am Heart J. 2005 Sep;150(3):392-400 [16169313.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6508-15 [16170160.001]
  • [Cites] Nat Clin Pract Oncol. 2004 Nov;1(1):26-31 [16264796.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2638-42 [16258932.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):143-8 [16317758.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):169-73 [16320315.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):149-58 [16369924.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1829-37 [16541445.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 May 19;55(19):529-32 [16708056.001]
  • [Cites] Circulation. 2006 Jul 11;114(2):168-82 [16801458.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Clin Oncol. 2006 Nov 10;24(32):5160-5 [17093280.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5277-82 [17088567.001]
  • [Cites] Circulation. 2007 Feb 6;115(5):e69-171 [17194875.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jun 15;48(7):723-6 [17226844.001]
  • (PMID = 17662616.001).
  • [ISSN] 1047-2797
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000400; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / M01-RR00400; United States / NCI NIH HHS / CA / K23 CA085503; United States / NCI NIH HHS / CA / CA106778-01; United States / NCI NIH HHS / CA / R21 CA106778; United States / NCI NIH HHS / CA / R21-CA106778; United States / NCI NIH HHS / CA / K23-CA85503; United States / NCRR NIH HHS / RR / M01 RR000400-370599; United States / NCI NIH HHS / CA / U24-CA55727; United States / NCRR NIH HHS / RR / RR000400-385932; United States / NCRR NIH HHS / RR / M01 RR000400-385932; United States / NCRR NIH HHS / RR / RR000400-370599; United States / NCI NIH HHS / CA / R21 CA106778-01; United States / NCI NIH HHS / CA / CA106778-02; United States / NCI NIH HHS / CA / R21 CA106778-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS31507; NLM/ PMC2036017
  •  go-up   go-down


19. Hockenberry M, Krull K, Moore K, Gregurich MA, Casey ME, Kaemingk K: Longitudinal evaluation of fine motor skills in children with leukemia. J Pediatr Hematol Oncol; 2007 Aug;29(8):535-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal evaluation of fine motor skills in children with leukemia.
  • BACKGROUND: Improved survival for children with acute lymphocytic leukemia (ALL) has allowed investigators to focus on the adverse or side effects of treatment and to develop interventions that promote cure while decreasing the long-term effects of therapy.
  • [MeSH-major] Motor Skills. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762494.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, Franklin J, Siegel SE, Seibel NL, Rogers PC, Sather H, Trigg M, Bleyer WA, Carroll WL: Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol; 2007 May 20;25(15):2063-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and outcome in pediatric acute lymphoblastic leukemia.
  • PURPOSE: To evaluate the effect of obesity (defined as a body mass index > 95th percentile for age and sex at diagnosis) on outcome of pediatric acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Obesity / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


21. Sidhom I, Shaaban K, Soliman S, Ezzat S, El-Anwar W, Hamdy N, Yassin D, Salem S, Hassanein H, Mansour MT: Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia. J Egypt Natl Canc Inst; 2008 Jun;20(2):111-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.
  • BACKGROUND: Cell-marker profiling has led to conflicting conclusions about its prognostic significance in T-ALL.
  • AIM: To investigate the prevalence of the expression of CD34, CD10 and myeloid associated antigens (CD13/ CD33) in childhood T-ALL and to relate their presence to initial clinical and biologic features and early response to therapy.
  • No significant association was encountered between CD34, CD10 or myeloid antigen positivity and the presenting clinical features as age, sex, TLC and CNS leukemia.
  • CD34 and CD13/CD33 expression was significantly associated with T-cell maturation stages (p<0.05).
  • CD34(+), CD13/CD33(+) and early T-cell stage had high MRD levels on day 15 that was statistically highly significant (p<0.01), but CD10(+) had statistically significant lower MRD level on day 15 (p=0.049).
  • CONCLUSIONS: CD34, CD10, CD13/CD33 expression, as well as T-cell maturation stages, may have prognostic significance in pediatric T-ALL as they have a significant impact on early clearance of leukemic cells detected by MRD day 15.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasm, Residual / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antigens, CD / metabolism. Antigens, CD13 / metabolism. Antigens, CD34 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Differentiation. Child. Child, Preschool. Egypt. Female. Flow Cytometry. Humans. Immunophenotyping. Infant. Male. Neprilysin / metabolism. Prognosis. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029466.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


22. Robien K, Ness KK, Klesges LM, Baker KS, Gurney JG: Poor adherence to dietary guidelines among adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Nov;30(11):815-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor adherence to dietary guidelines among adult survivors of childhood acute lymphoblastic leukemia.
  • Recent studies indicate that survivors of childhood acute lymphoblastic leukemia (ALL) are at increased risk of obesity and cardiovascular disease, conditions that healthy dietary patterns may help ameliorate or prevent.
  • To evaluate the usual dietary intake of adult survivors of childhood ALL, food frequency questionnaire data were collected from 72 participants, and compared with the 2007 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Cancer Prevention recommendations, the Dietary Approaches to Stop Hypertension (DASH) diet, and the 2005 United States Department of Agriculture (USDA) Food Guide.
  • These findings suggest that dietary intake for many adult survivors of childhood ALL is not concordant with dietary recommendations that may help reduce their risk of obesity, cardiovascular disease, or other treatment-related late effects.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Eur J Cancer Care (Engl). 2001 Mar;10(1):12-20 [11827263.001]
  • [Cites] J Am Diet Assoc. 2002 Feb;102(2):212-25 [11846115.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] JAMA. 2002 Apr 10;287(14):1832-9 [11939869.001]
  • [Cites] J Am Diet Assoc. 2002 Jun;102(6):801-8 [12067045.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1204-9 [12439706.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):189-96 [12525509.001]
  • [Cites] J Am Diet Assoc. 2003 Mar;103(3):323-8 [12616253.001]
  • [Cites] Int J Epidemiol. 2003 Dec;32(6):1054-62 [14681273.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):631-40 [14745882.001]
  • [Cites] J Am Diet Assoc. 2004 Apr;104(4):615-35 [15054348.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1114-20 [15247121.001]
  • [Cites] Psychooncology. 2004 Sep;13(9):619-29 [15334530.001]
  • [Cites] J Am Diet Assoc. 2004 Oct;104(10):1561-8 [15389414.001]
  • [Cites] Med Pediatr Oncol. 1995 Sep;25(3):159-65 [7623724.001]
  • [Cites] N Engl J Med. 1997 Apr 17;336(16):1117-24 [9099655.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 4;90(3):219-25 [9462679.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):60-3 [10401499.001]
  • [Cites] Cancer. 2005 May 15;103(10):2171-80 [15812823.001]
  • [Cites] Oncology (Williston Park). 2005 Jun;19(7):871-81; discussion 881-2, 885-6 [16053036.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5814-30 [16043830.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6499-507 [16170159.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2826-8 [16364996.001]
  • [Cites] Eur J Clin Nutr. 2006 Sep;60(9):1046-54 [16482067.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Am Coll Nutr. 2006 Oct;25(5):370-81 [17031005.001]
  • [Cites] CA Cancer J Clin. 2006 Nov-Dec;56(6):323-53 [17135691.001]
  • [Cites] Am J Hypertens. 2007 Mar;20(3):225-32 [17324731.001]
  • [Cites] J Nutr. 2007 Nov;137(11):2443-50 [17951483.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • (PMID = 18989158.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000400; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / M01-RR00400; United States / NCI NIH HHS / CA / K23 CA085503; United States / NCI NIH HHS / CA / R21 CA106778; United States / NCI NIH HHS / CA / R21-CA106778; United States / NCI NIH HHS / CA / K23-CA85503; United States / NCI NIH HHS / CA / U24-CA55727; United States / NCI NIH HHS / CA / CA106778-02; United States / NCI NIH HHS / CA / R21 CA106778-02
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS87238; NLM/ PMC2633871
  •  go-up   go-down


23. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol; 2007 Mar 1;25(7):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
  • PURPOSE: Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children.
  • Adolescents were more likely to present with T-cell phenotype (P < .001) and less likely to have the TEL-AML1 fusion (P = .05).
  • CONCLUSION: Adolescents were more likely to present at diagnosis with biologically higher risk disease (T-cell phenotype and absence of the TEL-AML1 fusion) and more likely to experience treatment-related complications than younger children.
  • However, the 5-year EFS for older adolescents was 78% +/- 6%, which is superior to published outcomes for similarly aged patients treated with other pediatric and adult ALL regimens.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327603.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68484
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


24. Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group: The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer; 2008 Aug;51(2):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.
  • BACKGROUND: There have been excellent treatment results for children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell leukemia (B-ALL) in the last few decades.
  • Among 18 patients who had a chemotherapy-sensitive disease, 4 of 5 patients who underwent hematopoietic stem cell transplantation (HSCT) during remission survived without progression, while 3 of 12 patients who did not receive HSCT were alive without disease progression.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, B-Cell / therapy. Lymphoma, B-Cell / therapy


25. Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G, Yaniv I: Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer; 2009 Jan;52(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
  • BACKGROUND: Despite overlapping features of T-cell lymphoblastic lymphoma (T-LLy) and T-cell acute lymphoblastic leukemia (T-ALL), which respond favorably to T-ALL treatment, clinical and biological differences exist.
  • PROCEDURE: Four-color flow cytometry (FC) was used for lymphoma associated immunophenotype and real-time quantitative polymerase chain reaction (RQ-PCR) for T-cell receptor (TCR beta/delta/gamma) gene rearrangements with at least 0.01% sensitivity.
  • [MeSH-major] Bone Marrow Diseases / diagnosis. Neoplasm, Residual / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tantawy AA, El-Bostany EA, Adly AA, Abou El Asrar M, El-Ghouroury EA, Abdulghaffar EE: Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis; 2010 Jan;21(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
  • Methotrexate is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5,10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate by methylene tetrahydrofolate reductase (MTHFR).
  • MTHFR TT genotype is significantly associated with increased mucosal and hepatic toxicity during methotrexate therapy as well as increased relapse rate in childhood ALL.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood Coagul Fibrinolysis. 2010 Mar;21(2):200
  • (PMID = 19923983.001).
  • [ISSN] 1473-5733
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


27. Sawczyn KK, Quinones R, Malcolm J, Foreman N, Garrington T, Gore L, Gao D, Giller R: Cord blood transplant in childhood ALL. Pediatr Blood Cancer; 2005 Dec;45(7):964-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cord blood transplant in childhood ALL.
  • BACKGROUND: Optimal therapy for high risk and relapsed acute lymphoblastic leukemia (ALL) remains uncertain.
  • Wider availability of cord blood from related and unrelated donors has prompted studies of its use for hematopoietic stem cell transplant (HSCT).
  • Median CB nucleated cell dose was 3.26e7/kg (range, 0.8-12.9).
  • Acute GVHD developed in 14/24 evaluable patients, reaching grade III-IV in 7 patients.
  • Multivariate analysis showed higher total nucleated cell dose per kilogram to be the strongest predictor of event-free survival.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2005 Dec;45(7):874-5 [16187299.001]
  • (PMID = 15929135.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Teuffel O, Schrauder A, Sykora KW, Zimmermann M, Reiter A, Welte K, Schrappe M: The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. Bone Marrow Transplant; 2005 Jul;36(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
  • Experimental and clinical data demonstrate an antileukemia effect of acute graft-versus-host disease (aGVHD).
  • In all, 58 pediatric patients with acute lymphoblastic leukemia (ALL) who had received an allogeneic bone marrow transplant (BMT) at our institution were retrospectively analyzed for a correlation between the development of aGVHD and leukemic relapse.
  • We therefore suggest that there is a relation between dose of CsA and relapse rate in childhood ALL transplanted from a MSD.
  • [MeSH-major] Bone Marrow Transplantation. Cyclosporine / administration & dosage. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect / drug effects. Immunosuppressive Agents / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


29. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer; 2008 Jun;50(6):1190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
  • The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP).
  • RESULTS: SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel.
  • SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18260118.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01-CM-42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / SCH 717454; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


30. Linsenmeier C, Thoennessen D, Negretti L, Bourquin JP, Streller T, Lütolf UM, Oertel S: Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation. Strahlenther Onkol; 2010 Nov;186(11):614-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation.
  • PURPOSE: To retrospectively analyze patient characteristics, treatment, and treatment outcome of pediatric patients with hematologic diseases treated with total body irradiation (TBI) between 1978 and 2006.
  • PATIENTS AND METHODS: 32 pediatric patients were referred to the Department of Radiation-Oncology at the University of Zurich for TBI.
  • A total of 18 patients suffered from acute lymphoblastic leukemia (ALL), 5 from acute and 2 from chronic myelogenous leukemia, 1 from non-Hodgkin lymphoma, and 2 from anaplastic anemia.
  • The cohort consisted of 15 patients referred after first remission and 13 patients with relapsed leukemia.
  • Overall survival was significantly inferior in patients treated after relapse compared to those treated for newly diagnosed leukemia (24% versus 74%; p=0.004).
  • Conditioning for bone marrow transplantation without radiation is an attractive option, but is not sufficiently effective to completely replace TBI for the most common pediatric indications.
  • [MeSH-major] Anemia, Aplastic / radiotherapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radiotherapy. Leukemia, Myeloid, Acute / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Whole-Body Irradiation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / etiology. Hematopoietic Stem Cell Transplantation. Humans. Male. Neoplasms, Radiation-Induced / etiology. Radiation Injuries / etiology. Radiotherapy Dosage. Recurrence. Remission Induction. Retreatment. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Apr 15;85(8):2263-8 [7718899.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1076-84 [12209694.001]
  • [Cites] Lancet. 1982 Feb 20;1(8269):437-9 [6121103.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Mar;11(3):223-30 [15744241.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1613-20 [15990868.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4215-22 [15701723.001]
  • [Cites] Haematologica. 2000 Oct;85(10):1060-7 [11025598.001]
  • [Cites] Blood. 1992 May 15;79(10):2578-82 [1586710.001]
  • [Cites] Strahlenther Onkol. 2008 Jul;184(7):376-80 [19016037.001]
  • [Cites] Radiother Oncol. 1990;18 Suppl 1:16-29 [2123356.001]
  • [Cites] Blood. 1994 Sep 15;84(6):2036-43 [8081005.001]
  • [Cites] Radiology. 1979 Apr;131(1):243-7 [370902.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(2):143-7 [15170172.001]
  • [Cites] Strahlenther Onkol. 2009 Nov;185(11):751-5 [19899009.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S14-7 [18545236.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3569-74 [11739158.001]
  • [Cites] Radiother Oncol. 1990;18 Suppl 1:60-7 [2247650.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:13-6 [19685028.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):464-71 [11208840.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:17-20 [19685029.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):637-45 [8652385.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):876-84 [16199317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Jul;9(7):1029-33 [6305894.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2187-93 [8471778.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):809-16 [14967438.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):991-5 [15806126.001]
  • [Cites] Strahlenther Onkol. 2008 Aug;184(8):406-10 [18956517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1568-75 [15990246.001]
  • [Cites] Bone Marrow Transplant. 1986 Dec;1(2):151-7 [3332129.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):672-9 [17072526.001]
  • (PMID = 21069270.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Bota DA, Dafer RM: Acute methotrexate neurotoxicity with choreiform movements and focal neurological deficits: a case report. South Med J; 2009 Oct;102(10):1071-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute methotrexate neurotoxicity with choreiform movements and focal neurological deficits: a case report.
  • Methotrexate (MTX) is an effective antimetabolite treatment for various oncological disorders including the central nervous system involvement (CNS) in widespread leukemia and CNS lymphoma.
  • This form of treatment has a notable toxic effect on the nervous system, and the pediatric population seems to be more vulnerable to the neurologic toxicity of this drug.
  • Though chronic leukoencephalopathy from an MTX regimen, especially when administered in conjunction with whole brain radiation, is well described, the acute manifestations are rare and not well understood.
  • The diagnosis of acute focal symptoms from MTX treatment is especially difficult in patients who receive chemotherapy for neoplastic disorders and who may have many reasons for CNS involvement in general and parenchymal involvement in particular.
  • We report the unusual clinical and neuro-imaging findings in a teenager with acute focal symptoms after MTX treatment for acute lymphoblastic leukemia.
  • [MeSH-minor] Acute Disease. Adolescent. Brain / pathology. Confusion / chemically induced. Headache / chemically induced. Humans. Magnetic Resonance Imaging. Male. Nausea / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Reflex, Abnormal / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738521.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


32. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2006;:133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult acute lymphoblastic leukemia.
  • In the early 1980s, adult acute lymphoblastic leukemia (ALL) was a rarely curable disease with overall survival < 10%.
  • After adapting combinations employed by pediatric groups, the outcome improved to 30-40%.
  • Improvements to standard therapy including stem cell transplantation (SCT) have occurred and a variety of new drugs for ALL are under evaluation.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124052.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


33. Akiyama M, Yamada O, Agawa M, Yuza Y, Yanagisawa T, Eto Y, Yamada H: Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Apr;30(4):313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia.
  • Although glucocorticoid is essential in the treatment of pediatric acute lymphoblastic leukemia (ALL), their precise mechanisms of action remain unclear.
  • We used DNA microarray to evaluate prednisolone-regulated genes in pre-B-ALL cells from 2 pediatric patients.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Lymphoma, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391702.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


34. Husak Z, Printz D, Schumich A, Pötschger U, Dworzak MN: Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. J Leukoc Biol; 2010 Aug;88(2):405-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors.
  • Our study was performed to examine the role of CD99 in normal and leukemia BCPs.
  • CD99 is strongly expressed by certain pediatric cancers including BCP-ALL.
  • We investigated BCP-ALL cases and normal BCP cells from pediatric BM for CD99 protein and RNA expression as well as for effects of CD99 modulation by mAb.
  • An association of CD99 expression levels with the cytogenetic background of pediatric BCP-ALLs was found.
  • CD99 ligation moderately induced cell death only in TEL/AML1 cases.
  • Stroma cell contact mitigated this effect.
  • We consider our results as an indication that CD99 may play a physiologic role in the clonal deletion processes necessary for B-lymphoid selection.
  • [MeSH-major] Antigens, CD / physiology. Cell Adhesion Molecules / physiology. Core Binding Factor Alpha 2 Subunit. Oncogene Proteins, Fusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antigens, CD99. Apoptosis. B-Lymphocytes / cytology. Cell Death. Child. Humans. Lymphopoiesis. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453109.001).
  • [ISSN] 1938-3673
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18196
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD99; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


35. Iqbal Z, Iqbal M, Akhter T: Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukemia (ALL) patients reflects ethnic differences in molecular genetics of ALL. J Pediatr Hematol Oncol; 2007 Aug;29(8):585
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukemia (ALL) patients reflects ethnic differences in molecular genetics of ALL.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Pediatr Hematol Oncol. 2007 Jan;29(1):27-31 [17230064.001]
  • (PMID = 17762503.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


36. Marinovic D, Dorgeret S, Lescoeur B, Alberti C, Noel M, Czernichow P, Sebag G, Vilmer E, Léger J: Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study. Pediatrics; 2005 Jul;116(1):e102-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
  • OBJECTIVES: Abnormalities in bone mineral density (BMD), body composition, and bone metabolism have been reported in children who were treated for acute lymphoblastic leukemia (ALL) during and after completion of therapy.
  • RESULTS: A slight decrease in TB BMD was found after a median time of 2.2 years after the completion of therapy for ALL in childhood.
  • [MeSH-major] Body Composition. Bone Density. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism


37. Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC: Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol; 2005 Mar;33(3):286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
  • OBJECTIVES: We and others have shown that B cell precursor acute lymphoblastic leukemia cells (ALL) stimulated with CD40 ligand become efficient antigen-presenting cells (APC) capable of expanding autologous, tumor-specific T cells from patients.
  • Despite recovery of myelopoiesis, most patients had profound defects in T, B, and natural killer (NK) cell numbers that failed to recover at any point during therapy.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy, Adoptive. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730852.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K08HL72750; United States / NCI NIH HHS / CA / P01CA68484
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Cancer Vaccines
  •  go-up   go-down


38. Molina F, Schramm C, Ruiz G: [Direct costs of pharmacotherapy for acute leukemia at a Regional Hospital in Chile]. Rev Med Chil; 2009 Dec;137(12):1553-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Direct costs of pharmacotherapy for acute leukemia at a Regional Hospital in Chile].
  • BACKGROUND: In Chile, leukemia is one of the diseases whose treatment is guaranteed by a special law called AUGE (universal access and explicit guaranties).
  • AIM: To determine and to characterize the direct costs of pharmacotherapy for leukemia at a regional hospital in Chile.
  • MATERIAL AND METHODS: Data were retrospectively obtained from electronic and manual records of the hospital for all patients treated for leukemia between 2003 and 2006.
  • Patients were classified into four groups: pediatric and adult patients treated for acute lymphocytic leukemia (ALL children and ALL adults, respectively), and pediatric and adult patients treated for acute myelogenous leukemia (AML children and AML adults, respectively).
  • RESULTS: Total accumulated costs of pharmacotherapy for acute leukemia between 2003 and 2006 were 304,724,845 Chilean pesos (USD 574,952).
  • CONCLUSIONS: Annual costs of pharmacotherapy per patient for acute leukemia in this regional hospital were approximately USD 4,717.
  • [MeSH-major] Antineoplastic Agents / economics. Health Care Costs / statistics & numerical data. Leukemia, Myeloid, Acute / economics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / economics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361130.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Boueva A, Bouvier R: Precursor B-cell lymphoblastic leukemia as a cause of a bilateral nephromegaly. Pediatr Nephrol; 2005 May;20(5):679-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic leukemia as a cause of a bilateral nephromegaly.
  • Nephromegaly and non-oliguric acute renal failure is an unusual manifestation of lymphoblastic infiltration of the kidneys.
  • We report the clinical history of a female child where a precursor B-cell lymphoblastic proliferation was diagnosed at the age of 21 months by a surgical renal biopsy for an unexplained bilateral nephromegaly.
  • Lymphoblastic infiltration should be suspected in any patient presenting with unexplained renal failure and enlarged kidneys.
  • [MeSH-major] Acute Kidney Injury / etiology. Acute Kidney Injury / pathology. Burkitt Lymphoma / complications. Kidney / pathology. Leukemic Infiltration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Med. 1990 Oct;80(4):564-7 [2244054.001]
  • [Cites] Radiology. 1982 Sep;144(4):759-66 [7111721.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):748-53 [3524795.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):1120-1 [6883276.001]
  • [Cites] Radiology. 1982 Apr;143(1):207-10 [6950453.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1480-90 [11075849.001]
  • [Cites] Pediatr Dev Pathol. 2002 Jan-Feb;5(1):45-53 [11815868.001]
  • [Cites] Clin Nephrol. 1992 Sep;38(3):142-4 [1395166.001]
  • [Cites] Cancer. 1976 Dec;38(6):2588-92 [793711.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):423-6 [7545781.001]
  • [Cites] N Engl J Med. 1978 Dec 28;299(26):1446-8 [362210.001]
  • [Cites] AJR Am J Roentgenol. 1985 Sep;145(3):611-6 [3895872.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):795-804 [9669342.001]
  • [Cites] Am J Med. 1962 Feb;32:184-207 [14492019.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):868-75 [11392884.001]
  • [Cites] J Am Soc Nephrol. 1997 Aug;8(8):1348-54 [9259365.001]
  • [Cites] Cancer. 1974 Jan;33(1):203-5 [4810095.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):18-31 [11190804.001]
  • (PMID = 15714312.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Aparicio G, Mollet J, Bartralot R, Bodet D, Heras C, Bassas P, Virós A, García-Patos V: Eruptive juvenile xanthogranuloma associated with relapsing acute lymphoblastic leukemia. Pediatr Dermatol; 2008 Jul-Aug;25(4):487-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eruptive juvenile xanthogranuloma associated with relapsing acute lymphoblastic leukemia.
  • Although most patients with juvenile xanthogranuloma have only cutaneous symptoms, recent articles have documented extracutaneous manifestations: systemic involvement of many organs has been reported and there is a known association between juvenile xanthogranuloma and childhood leukemia, most commonly juvenile chronic myelogenous leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Xanthogranuloma, Juvenile / complications


41. Davidsson J, Andersson A, Paulsson K, Heidenblad M, Isaksson M, Borg A, Heldrup J, Behrendtz M, Panagopoulos I, Fioretos T, Johansson B: Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet; 2007 Sep 15;16(18):2215-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3.
  • Although gain of 1q occurs in 25% of Burkitt lymphomas (BLs) and 10% of pediatric high hyperdiploid acute lymphoblastic leukemias (ALLs), little is known about the origin, molecular genetic characteristics and functional outcome of dup(1q) in these disorders.
  • [MeSH-major] Burkitt Lymphoma / genetics. Centromere / genetics. Chromosomes, Human, Pair 1 / genetics. DNA Methylation. Gene Expression Regulation, Leukemic. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Guide to Pharmacology. gene/protein/disease-specific - regulator of G-protein signaling 16 - data and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613536.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


42. Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ: Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer; 2005 Sep;45(3):281-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity.
  • BACKGROUND: Central nervous system (CNS) directed chemotherapy is replacing prophylactic cranial irradiation in treatment protocols for childhood acute lymphoblastic leukemia (ALL), mainly to reduce long-term neuropsychological sequelae.
  • CONCLUSIONS: CNS-directed chemotherapy, even in the absence of cranial irradiation, is associated with attentional dysfunction in survivors of childhood ALL, particularly in case of intensified treatment protocols.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Attention. Cognition Disorders / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15806539.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


43. Cooper TM: Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag; 2007 Dec;3(6):1135-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
  • T-cell malignancies have distinct biochemical, immunologic, and clinical features which set them apart from non-T-cell malignancies.
  • In the past, T-cell leukemia portended a worse prognosis than leukemia of B-cell origin.
  • Cure rates have improved with intensification of therapy and advanced understanding of the molecular genetics of T-cell malignancies.
  • Further advances in the treatment of T-cell leukemia will require the development of novel agents that can target specific malignancies without a significant increase in toxicity.
  • Clinical and pharmacokinetic investigations have established that nelarabine is active as a single agent which has led to exploration of an expanded role in the treatment of T-cell hematologic malignances.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] J Immunol. 1990 Jan 15;144(2):485-91 [2104895.001]
  • [Cites] Leukemia. 1990 Nov;4(11):739-44 [2232884.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1817-21 [2306735.001]
  • [Cites] Blood. 1988 Dec;72(6):1891-7 [3058229.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Oct;75(10):5011-4 [311004.001]
  • [Cites] Lancet. 1975 May 3;1(7914):1010-3 [48676.001]
  • [Cites] J Biol Chem. 1968 Aug 25;243(16):4298-304 [5684726.001]
  • [Cites] Biochem J. 1983 Sep 15;214(3):711-8 [6312962.001]
  • [Cites] Blood. 1983 Apr;61(4):660-6 [6600944.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1517-24 [7533664.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3352-6 [7614470.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] Leukemia. 1993 Aug;7(8):1261-7 [8350627.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2110-7 [8471769.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Blood. 1998 Feb 1;91(3):735-46 [9446631.001]
  • [Cites] J Clin Invest. 1978 May;61(5):1405-9 [96138.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2107-13 [9815603.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4937-43 [10519407.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2196-204 [11187911.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2142-52 [11304766.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):321-31 [11378544.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3100-5 [12036920.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Dec;15(4):741-56 [12617874.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1842-8 [12750168.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • (PMID = 18516261.001).
  • [ISSN] 1176-6336
  • [Journal-full-title] Therapeutics and clinical risk management
  • [ISO-abbreviation] Ther Clin Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2387290
  • [Keywords] NOTNLM ; 9-β-D-arabinofuranosylguanine / T-cell acute lymphoblastic leukemia / nelarabine
  •  go-up   go-down


44. Kato I, Manabe A, Aoyama C, Kamiya T, Morimoto T, Matsufuji H, Suzuki K, Kitagawa Y, Hori T, Tsurusawa M, Kiyokawa N, Junichiro F, Hosoya R: Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Feb;48(2):230-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia.
  • Non-Hodgkin lymphoma (NHL) is a very rare complication of acute lymphoblastic leukemia (ALL).
  • While he was receiving maintenance treatment 2 years and 9 months after the diagnosis of ALL, diffuse large B cell lymphoma (DLBL) was diagnosed from a biopsy of an abdominal mass.
  • [MeSH-major] Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


45. Talano JM, Casper JT, Camitta BM, Keever-Taylor CA, Murray KJ, Eapen M, Pierce KL, Margolis DA: Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. Bone Marrow Transplant; 2006 Jan;37(2):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) have only a 20% event-free survival when treated with chemotherapy alone.
  • Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion (antibody T10B9 or OKT3 and complement) with post transplant cyclosporine (CSA).
  • Four developed grades III-IV acute GVHD.
  • [MeSH-major] Bone Marrow Transplantation. Donor Selection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273115.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


46. Molina B, Lassaletta A, Andion M, Gonzalez-Vicent M, López-Pino MA, Madero L: A persistent epidural mass in a child with B-lineage ALL. Pediatr Blood Cancer; 2010 Oct;55(4):727-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidural spinal cord compression as the initial presentation of acute lymphoblastic leukemia (ALL) is a rare and serious complication.
  • [MeSH-major] Epidural Neoplasms / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20535830.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Park JA, Ghim T, Bae KW, Koh KN, Im HJ, Seo JJ: Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant. Korean J Hematol; 2010 Jun;45(2):109-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant.
  • BACKGROUND: Despite advances in chemotherapy, the prognosis of relapsed acute lymphoblastic leukemia (ALL) remains poor.
  • Few studies on relapsed ALL have reported the importance of intensive consolidation followed with or without allogeneic hematopoietic stem cell transplantation (HSCT).
  • We found that second remission, consolidation of pediatric oncology group chemotherapy regimen (POG 9411), and HSCT significantly affected the outcome of the disease after relapse (P<0.001; P=0.004; P=0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120189.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2983016
  • [Keywords] NOTNLM ; Acute lymphoblastic leukemia / Hematopoietic stem cell transplantation / Intensive consolidation / Relapse
  •  go-up   go-down


48. Jaing TH, Lin JL, Lin YP, Yang SH, Lin JJ, Hsia SH: Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Dec;31(12):955-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia.
  • It is characterized by acute alteration in mental status and respiratory alkalosis associated with markedly elevated plasma ammonium levels in the absence of any identifiable cause and frequently results in cerebral edema, coma, and eventually death.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hyperammonemia / chemically induced. Neurotoxicity Syndromes / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887962.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


49. Loutfy SA, Alam El-Din HM, Ibrahim MF, Hafez MM: Seroprevalence of herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus in children with acute lymphoblastic leukemia in Egypt. Saudi Med J; 2006 Aug;27(8):1139-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seroprevalence of herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus in children with acute lymphoblastic leukemia in Egypt.
  • This study aimed at studying seroprevalence of 3 herpes viruses Herpes simplex virus types 1 and 2 (HSV 1 and 2), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) in children with acute lymphoblastic leukemia (ALL).
  • METHODS: We conducted this study on 68 newly diagnosed pediatric patients with ALL presented to the Pediatric Oncology Service of National Cancer Institute, Cairo University, Egypt from November 2001 to June 2003.
  • [MeSH-major] Herpesvirus 1, Human / isolation & purification. Herpesvirus 2, Human / isolation & purification. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883441.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


50. Horinouchi M, Yagi M, Imanishi H, Mori T, Yanai T, Hayakawa A, Takeshima Y, Hijioka M, Okamura N, Sakaeda T, Matsuo M, Okumura K, Nakamura T: Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol; 2010 Aug;27(5):344-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma.
  • The objective of this study was to identify novel pharmacogenetic determinants of treatment-related hepatotoxicity during the maintenance phase in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).
  • This study suggested rs1966862 (ARHGAP24) and the other SNPs to be predictive factors for drug-induced hepatotoxicity during the maintenance phase in pediatric patients with ALL or LBL.
  • [MeSH-major] Drug-Induced Liver Injury / genetics. Genetic Association Studies. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


51. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S: Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion; 2006;74(1):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.
  • L-Asparaginase is commonly used in combination chemotherapy of both pediatric and adult acute lymphoblastic leukemia.
  • We report here an adult patient who developed mixed liver injury and predominantly microvesicular hepatic steatosis while being treated with L-asparaginase for acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Asparaginase / adverse effects. Liver Failure / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988508.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


52. Jamroziak K, Robak T: Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia? Leuk Res; 2008 Aug;32(8):1173-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?
  • It is widely accepted that pathogenesis of childhood acute lymphoblastic leukemia (ALL) is related to the interplay between specific environmental exposure and inherited background.
  • Here, we review several recent reports on potential association between single nucleotide polymorphisms (SNPs) in genes encoding for ABC transporters with predisposition to pediatric ALL.
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Res. 2008 Aug;32(8):1214-20 [18243305.001]
  • (PMID = 18294687.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Comment
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1
  •  go-up   go-down


53. Baytan B, Gunes AM, Gunay U: Efficacy of primary hepatitis B immunization in children with acute lymphoblastic leukemia. Indian Pediatr; 2008 Apr;45(4):265-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of primary hepatitis B immunization in children with acute lymphoblastic leukemia.
  • BACKGROUND: Children with acute lymphoblastic leukemia (ALL) carry a high risk of hepatitis B virus (HIV) infection.
  • [MeSH-major] Hepatitis B / prevention & control. Hepatitis B Antibodies. Hepatitis B Vaccines. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology


54. Katzilakis N, Paraskakis E, Mantadakis E, Stiakaki E, Kalmanti M: Bronchial asthma and acute lymphoblastic leukemia in childhood. Pediatr Pulmonol; 2008 Feb;43(2):206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchial asthma and acute lymphoblastic leukemia in childhood.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Asthma / drug therapy. Asthma / prevention & control. Immunosuppressive Agents / administration & dosage. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / adverse effects. Drug Administration Schedule. Drug Therapy, Combination. Humans


55. Valera ET, Brassesco MS, Germeshausen M, Silveira Vda S, Queiroz RG, Roxo P, Scrideli CA, de Menezes UP, Ferriani V, Tone LG: Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL? Leuk Res; 2009 Sep;33(9):e139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL?
  • Acute lymphoblastic leukemia (ALL) presenting with neutropenia alone is very rare.
  • [MeSH-major] Neutropenia / congenital. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398129.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Kan JH, Hernanz-Schulman M, Frangoul HA, Connolly SA: MRI diagnosis of bone marrow relapse in children with ALL. Pediatr Radiol; 2008 Jan;38(1):76-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Diffuse marrow replacement in acute leukemia is well known, but there are few reports describing the MRI features of pediatric leukemic relapse.
  • OBJECTIVE: Our purpose was to describe the MRI appearance of pediatric leukemic relapse.
  • From this group, 14 children seen at initial diagnosis of leukemia and 2 children who underwent MRI after therapy for relapse were excluded.
  • CONCLUSION: Well-defined nodules in all patients with leukemic relapse suggest that this appearance is characteristic and distinct from the published findings of diffuse marrow replacement in acute leukemia.
  • [MeSH-major] Bone Marrow Diseases / diagnosis. Magnetic Resonance Imaging / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Paediatr Scand Suppl. 1974;(252):1-20 [4618418.001]
  • [Cites] Acta Paediatr Scand. 1981 Nov;70(6):879-83 [7324941.001]
  • [Cites] J Urol. 1991 Aug;146(2 ( Pt 2)):665-8 [1861322.001]
  • [Cites] Semin Nucl Med. 1992 Apr;22(2):98-111 [1317065.001]
  • [Cites] Acta Paediatr Scand. 1989 Nov;78(6):923-9 [2557721.001]
  • [Cites] Radiology. 1986 Jul;160(1):237-40 [3459212.001]
  • [Cites] Arch Dis Child. 2003 Aug;88(8):688-94 [12876164.001]
  • [Cites] J Urol. 2004 Sep;172(3):1071-3; discussion 1073-4 [15311040.001]
  • [Cites] Pediatr Radiol. 2006 Nov;36(11):1119-32; quiz 1228-9 [16791588.001]
  • [Cites] Pediatrics. 2000 Jun;105(6):1236-41 [10835063.001]
  • [Cites] J Urol. 1988 Nov;140(5 Pt 2):1169-74 [2846898.001]
  • [Cites] J Urol. 1983 Jun;129(6):1102-6 [6343637.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 2):1548-50 [14501657.001]
  • [Cites] J Urol. 1999 Jun;161(6):1928-33 [10332475.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1743-5 [1433600.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):559-63 [8410507.001]
  • [Cites] Radiology. 1991 Nov;181(2):587-9 [1924809.001]
  • [Cites] J Urol. 2004 Sep;172(3):1075-7; discussion 1077 [15311041.001]
  • [Cites] N Z Med J. 1995 Apr 26;108(998):142-4 [7761049.001]
  • [Cites] Pediatr Nephrol. 1993 Aug;7(4):361-4 [8398641.001]
  • [Cites] J Pediatr. 2000 Jan;136(1):30-4 [10636970.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] Arch Dis Child. 1995 May;72 (5):393-6 [7618903.001]
  • [Cites] Radiology. 1998 May;207 (2):377-84 [9577484.001]
  • [Cites] J Urol. 1996 May;155(5):1711-5 [8627867.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1994 Mar;70(2):F147-9; discussion 149-50 [7802758.001]
  • [Cites] BJU Int. 2000 Jul;86(1):94-6 [10886091.001]
  • [Cites] Nephron. 1982;30(3):262-8 [7099339.001]
  • [Cites] Pediatr Radiol. 1990;20(3):179-83 [2352796.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):941-6 [3656575.001]
  • [Cites] Lancet. 1973 Jul 7;2(7819):1-4 [4123292.001]
  • [Cites] Pediatr Radiol. 1990;20(4):272-6 [2336289.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):279-82 [15224367.001]
  • [Cites] Arch Dis Child. 1991 Nov;66(11):1282-3 [1661570.001]
  • [Cites] J Urol. 1998 Sep;160(3 Pt 2):1019-22 [9719268.001]
  • [Cites] J Urol. 1975 Aug;114(2):274-80 [1171997.001]
  • [Cites] Clin Radiol. 1960 Oct;11:219-31 [13714877.001]
  • [Cites] Pediatr Nephrol. 1997 Feb;11(1):108-20 [9035184.001]
  • [Cites] BMJ. 1994 May 7;308(6938):1193-6 [8180534.001]
  • [Cites] Urology. 1999 Apr;53(4):812-5 [10197863.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Urol. 2006 Oct;176(4 Pt 2):1786-92 [16945650.001]
  • [Cites] J Urol. 2005 Mar;173(3):697-704 [15711246.001]
  • [Cites] Pediatrics. 2006 Mar;117(3):626-32 [16510640.001]
  • [Cites] Clin Nephrol. 1973 May-Jun;1(3):132-41 [4783715.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1674-5 [1433586.001]
  • [Cites] J Urol. 2000 Nov;164(5):1674-8; discussion 1678-9 [11025746.001]
  • [Cites] Br Med J. 1965 Apr 17;1(5441):1023-6 [14262192.001]
  • [Cites] J Urol. 2005 Feb;173(2):571-4; discussion 574-5 [15643259.001]
  • [Cites] Infect Dis Clin North Am. 1987 Dec;1(4):713-29 [3333655.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2002 Feb;32(2):40-9 [11951089.001]
  • [Cites] J Urol. 1976 Oct;116(4):503-5 [1053345.001]
  • [Cites] Radiology. 1991 Jan;178(1):193-6 [1984303.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):163 [15813842.001]
  • [Cites] Pediatrics. 1999 Apr;103(4 Pt 1):843-52 [10103321.001]
  • [Cites] Pediatr Nephrol. 1998 Nov;12 (9):727-36 [9874316.001]
  • [Cites] J Am Soc Nephrol. 2003 Mar;14 (3):739-44 [12595511.001]
  • [Cites] J Pediatr. 1996 Jan;128(1):15-22 [8551409.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1653-6 [1433582.001]
  • [Cites] Pediatr Nephrol. 2006 Jun;21(6):785-92 [16565873.001]
  • (PMID = 17994232.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


57. Unal S, Tuncer AM, Cetin M, Yetgin S: The absence of peripheral blood blasts at diagnosis may predict CNS involvement or CNS relapse in pediatric acute lymphoblastic leukemia patients. Turk J Pediatr; 2008 Nov-Dec;50(6):537-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The absence of peripheral blood blasts at diagnosis may predict CNS involvement or CNS relapse in pediatric acute lymphoblastic leukemia patients.
  • A high tumor burden at the time of diagnosis of childhood acute lymphoblastic leukemia has an unfavorable outcome.
  • Peripheral white blood cell count is commonly used to reflect the leukemic burden and is used as one of the most important factors during determination of the risk-based treatment.
  • [MeSH-major] Blast Crisis / pathology. Central Nervous System Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227416.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


58. Slats AM, Egeler RM, van der Does-van den Berg A, Korbijn C, Hählen K, Kamps WA, Veerman AJ, Zwaan CM: Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia; 2005 Apr;19(4):537-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience.
  • We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols.
  • [MeSH-major] Leukemia, Myeloid / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Agents / adverse effects. Cause of Death. Child. Child, Preschool. Female. Humans. Infant. Male. Netherlands / epidemiology. Remission Induction


59. Lamb LS Jr, Neuberg R, Welsh J, Best R, Stetler-Stevenson M, Sorrell A: T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia. Cytometry B Clin Cytom; 2005 May;65(1):37-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia.
  • This case represents an example of an unusual T-cell lymphoblastic leukemia/lymphoma syndrome associated with eosinophilia and myeloid malignancy in a young boy.
  • This case is one of only five reported "leukemic" variants of the disease and demonstrates the importance of considering this poor prognostic diagnosis in pediatric acute lymphoblastic leukemia.
  • This case also illustrates the importance of an interactive multidisciplinary approach to the laboratory evaluation of a leukemia patient.
  • [MeSH-major] Eosinophilia / complications. Leukemia, Myeloid, Acute / complications. Leukemia-Lymphoma, Adult T-Cell / complications. Lymphoma / complications


60. Brown P, Smith FO: Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date. Paediatr Drugs; 2008;10(2):85-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.
  • While acute myeloid leukemia (AML) is significantly less common than acute lymphoblastic leukemia (ALL) in childhood, it is significantly more deadly with only half as many children likely to be cured with standard therapy.
  • In addition, the typical treatment for AML is among the most toxic of treatments for pediatric cancer; it includes intensive multiagent chemotherapy and, often, hematopoietic stem cell transplantation.
  • Given the poor prognosis of pediatric AML and the significant toxicity of standard AML therapy, novel therapies are needed.
  • Improved understanding of the molecular and cellular biology of leukemia has facilitated the development of molecularly targeted therapies.
  • In this article, we review progress to date with agents that are showing promise in the treatment of pediatric AML including targeted immunoconjugates, inhibitors of signaling molecules (e.g.
  • Finally, we discuss potential challenges to the success of molecularly targeted therapy including demonstrating adequate targeting of leukemia stem cells, developing synergistic and tolerable combinations of agents, and designing adequately powered clinical trials to test efficacy in molecularly defined subsets of patients.
  • [MeSH-major] Leukemia, Myeloid, Acute

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Oct 15;108(8):2764-9 [16809615.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):565-9 [16261562.001]
  • [Cites] Leukemia. 2003 May;17 (5):995-7 [12750723.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1811-6 [1373089.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1277-84 [15735013.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):207-22 [16321850.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • [Cites] Blood. 2007 Feb 15;109 (4):1387-94 [17082323.001]
  • [Cites] Blood. 2001 Oct 15;98 (8):2301-7 [11588023.001]
  • [Cites] Leukemia. 1999 Jan;13(1):38-43 [10049058.001]
  • [Cites] Int J Hematol. 2005 Aug;82(2):100-7 [16146839.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2043-56 [10068678.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4168-70 [17227830.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2005-12 [7718872.001]
  • [Cites] Curr Hematol Rep. 2004 May;3(3):203-9 [15087069.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):525-9 [10573574.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1841-9 [15166029.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):837-41 [9041182.001]
  • [Cites] Blood. 1999 May 15;93(10):3302-8 [10233882.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1516-22 [17332297.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3058-65 [15626743.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5165-73 [16951235.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4276-84 [14962898.001]
  • [Cites] Blood. 1997 Jul 15;90(2):489-519 [9226149.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Leukemia. 2003 Feb;17(2):350-8 [12592335.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jun;321(3):953-60 [17389244.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23 ):4816-22 [15570084.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Eur J Clin Invest. 2007 Jan;37(1):73-82 [17181570.001]
  • [Cites] Blood. 2003 Aug 1;102(3):972-80 [12702506.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1333-7 [9737679.001]
  • [Cites] Leukemia. 2003 Jan;17 (1):83-8 [12529664.001]
  • [Cites] Blood. 2005 Jul 15;106(2):673-80 [15797998.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2325-31 [14644997.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):811-4 [9486654.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1466-73 [12689934.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5 [12451177.001]
  • [Cites] Blood. 2005 Jul 1;106(1):345-52 [15774615.001]
  • [Cites] Blood. 2000 Jan 15;95(2):639-45 [10627474.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Cell Growth Differ. 1992 Jul;3(7):461-9 [1419908.001]
  • [Cites] Leukemia. 2002 May;16(5):813-9 [11986941.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Science. 2002 Feb 8;295(5557):1079-82 [11834837.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S30-5 [16341238.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3371-6 [15161691.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Adv Exp Med Biol. 2003;532:121-40 [12908554.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]
  • [Cites] Br J Haematol. 1991 Mar;77(3):323-7 [2012756.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1932-42 [10602413.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2527-34 [15550488.001]
  • [Cites] Leukemia. 1987 Oct;1(10):697-705 [3312833.001]
  • [Cites] Blood. 2001 Aug 15;98 (4):988-94 [11493443.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):707-21, discussion 722-4 [15010072.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2707-16 [16981007.001]
  • [Cites] Cell Cycle. 2006 Feb;5(3):271-3 [16397415.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Semin Hematol. 2004 Apr;41(2 Suppl 4):27-32 [15190513.001]
  • [Cites] Leukemia. 2004 Mar;18(3):375-84 [14737069.001]
  • [Cites] Blood. 2007 Jun 15;109 (12 ):5151-6 [17351110.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] Blood. 1993 Aug 1;82(3):792-9 [8338945.001]
  • [Cites] Lancet. 2007 Jul 28;370(9584):342-50 [17662883.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):815-8 [9486655.001]
  • (PMID = 18345718.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA111728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Proteasome Inhibitors; 0 / Protein Kinase Inhibitors; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 92
  •  go-up   go-down


61. El-Sharnouby JA, Abou El-Enein AM, El Ghannam DM, El-Shanshory MR, Hagag AA, Yahia S, Elashry R: Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia. J Oncol Pharm Pract; 2010 Sep;16(3):179-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia.
  • The prognostic value that lung resistance protein (LRP) and multidrug resistance-related protein 1 (MRP1) have in the setting of pediatric acute lymphoblastic leukemia (ALL) is controversial.
  • The mRNA expression of LRP and MRP1 were analyzed in leukemic blasts of 34 pediatric ALL patients.
  • Thus, diagnosis appears to provide prognostic information for pediatric ALL.
  • [MeSH-major] Multidrug Resistance-Associated Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / biosynthesis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19969624.001).
  • [ISSN] 1477-092X
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1
  •  go-up   go-down


62. Okamoto R, Ogawa S, Nowak D, Kawamata N, Akagi T, Kato M, Sanada M, Weiss T, Haferlach C, Dugas M, Ruckert C, Haferlach T, Koeffler HP: Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica; 2010 Sep;95(9):1481-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Differences in survival have been reported between pediatric and adult acute lymphoblastic leukemia.
  • The inferior prognosis in adult acute lymphoblastic leukemia is not fully understood but could be attributed, in part, to differences in genomic alterations found in adult as compared to in pediatric acute lymphoblastic leukemia.
  • DESIGN AND METHODS: We compared two different sets of high-density single nucleotide polymorphism array genotyping data from 75 new diagnostic adult and 399 previously published diagnostic pediatric acute lymphoblastic leukemia samples.
  • RESULTS: The high density single nucleotide polymorphism array analysis of 75 samples of adult acute lymphoblastic leukemia led to the identification of numerous cryptic and submicroscopic genomic lesions with a mean of 7.6 genomic alterations per sample.
  • The patterns and frequencies of lesions detected in the adult samples largely reproduced known genomic hallmarks detected in previous single nucleotide polymorphism-array studies of pediatric acute lymphoblastic leukemia, such as common deletions of 3p14.2 (FHIT), 5q33.3 (EBF), 6q, 9p21.3 (CDKN2A/B), 9p13.2 (PAX5), 13q14.2 (RB1) and 17q11.2 (NF1).
  • Some differences between adult and pediatric acute lymphoblastic leukemia were identified when the pediatric data set was partitioned into hyperdiploid and non-hyperdiploid cases and then compared to the nearly exclusively non-hyperdiploid adult samples.
  • CONCLUSIONS: Our analysis of adult acute lymphoblastic leukemia cases led to the identification of new potential target lesions relevant for the pathogenesis of acute lymphoblastic leukemia.
  • However, no unequivocal pattern of submicroscopic genomic alterations was found to separate adult acute lymphoblastic leukemia from pediatric acute lymphoblastic leukemia.
  • Therefore, apart from different therapy regimen, differences of prognosis between adult and pediatric acute lymphoblastic leukemia are probably based on genetic subgroups according to cytogenetically detectable lesions but not focal genomic copy number microlesions.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):477-87 [18297524.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11921-6 [18697940.001]
  • [Cites] Leukemia. 2009 Jan;23(1):134-43 [19020546.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Haematologica. 2009 Apr;94(4):518-27 [19278963.001]
  • [Cites] Int J Oncol. 2009 Jun;34(6):1603-12 [19424578.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3089-97 [20160164.001]
  • [Cites] Haematologica. 2009 Feb;94(2):213-23 [19144660.001]
  • [Cites] Immunity. 2000 Dec;13(6):817-27 [11163197.001]
  • [Cites] J Exp Med. 2002 Mar 4;195(5):535-45 [11877477.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):175-84 [14734530.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] EMBO J. 1992 Apr;11(4):1663-70 [1373383.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5513-23 [8355697.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):162-74 [15826831.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Dec;44(4):405-14 [16114034.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3673-80 [16585193.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3417-23 [17179230.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):661-9 [17420988.001]
  • [Cites] Am J Hum Genet. 2007 Jul;81(1):114-26 [17564968.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):269-74 [17897302.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • (PMID = 20435627.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA026038-31; United States / NCI NIH HHS / CA / R01 CA026038-32; United States / NCI NIH HHS / CA / CA026038-30A2; United States / NCI NIH HHS / CA / R01 CA026038; United States / NCI NIH HHS / CA / R01 CA026038-30A2
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2930948
  •  go-up   go-down


63. Baillargeon J, Langevin AM, Lewis M, Grady JJ, Thomas PJ, Mullins J, Estrada J, Pitney A, Sacks N, Pollock BH: Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia. Cancer; 2005 Apr 15;103(8):1725-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia.
  • BACKGROUND: The objective of this study was to examine changes over time in body mass index (BMI) from diagnosis through chemotherapy for pediatric patients with B-precursor acute lymphoblastic leukemia (ALL).
  • METHODS: The study cohort consisted of 141 white Hispanic pediatric patients who were diagnosed with ALL and were treated at 2 South Texas pediatric oncology centers between 1993 and 2002.
  • CONCLUSIONS: Although it is known that leukemia therapy is associated with prevalent obesity in survivorship, its pattern of development during therapy has not been elucidated.
  • [MeSH-major] Body Mass Index. Obesity / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15754333.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11078
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


64. Steinherz PG, Shukla N, Kobos R, Steinherz L: Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer; 2010 May;54(5):687-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
  • BACKGROUND: We determined the maximum tolerated dose (MTD) of clofarabine when administered with topotecan, vinorelbine, thiotepa, and dexamethasone (TVTC) for children with relapsed or refractory acute leukemia, and observed the efficacy and toxicities of this therapy.
  • PROCEDURE: Twelve patients with acute lymphoblastic or myeloblastic leukemia were given a 14-day remission induction therapy.
  • Patients who achieved a remission proceeded to a stem cell transplant (HSCT).
  • One patient died on day 45 with marrow hypoplasia without evidence of leukemia.
  • CONCLUSION: TVTC has significant anti-leukemic activity in both acute lymphoblastic and myeloblastic leukemia.
  • This is the recommended dose for the phase II study in patients with refractory or relapsed leukemia, a population which has limited therapeutic options.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adenine Nucleotides / administration & dosage. Adenine Nucleotides / adverse effects. Adolescent. Adult. Arabinonucleosides / administration & dosage. Arabinonucleosides / adverse effects. Child. Child, Preschool. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Maximum Tolerated Dose. Recurrence. Remission Induction. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 5V9KLZ54CY / Vinblastine; 762RDY0Y2H / clofarabine; 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


65. Berman JN, Look AT: Targeting transcription factors in acute leukemia in children. Curr Drug Targets; 2007 Jun;8(6):727-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting transcription factors in acute leukemia in children.
  • Transcription factors play essential roles in controlling normal blood development and their alteration leads to abnormalities in cell proliferation, differentiation and survival.
  • In many childhood acute leukemias, transcription factors are altered through chromosomal translocations that change their functional properties resulting in repressed activity or inappropriate activation.
  • The development of therapies that specifically target these molecular abnormalities holds promise for improving the outcome in diseases that remain challenging to treat, such as childhood T-cell acute lymphoblastic leukemia and acute myeloid leukemia, with improved toxicity profiles.
  • All trans-retinoic acid and arsenic trioxide have already demonstrated efficacy in acute promyelocytic leukemia in both adults and children.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Delivery Systems. Leukemia / drug therapy. Transcription Factors / drug effects
  • [MeSH-minor] Acute Disease. Arsenicals / pharmacology. Arsenicals / therapeutic use. Child. DNA Methylation / drug effects. Histone Deacetylase Inhibitors. Humans. Oxides / pharmacology. Oxides / therapeutic use. Tretinoin / pharmacology. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17584028.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Histone Deacetylase Inhibitors; 0 / Oxides; 0 / Transcription Factors; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 113
  •  go-up   go-down


66. Makki MS, Heinzel T, Englert C: TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. Nucleic Acids Res; 2008 Jul;36(12):4067-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Wilms tumor gene WT1 encodes a zinc-finger transcription factor that is inactivated in a subset of pediatric kidney cancers.
  • Although widely regarded as a tumor suppressor gene, wild-type WT1 is overexpressed in a variety of hematologic malignancies, most notably in acute lymphoblastic leukemia as well as myelodysplastic syndromes.
  • We show here that histone deacetylase inhibitors like Trichostatin A (TSA) can promptly and dramatically downregulate Wt1 expression levels in different cell lines.
  • [MeSH-minor] Animals. Cell Line. Cell Line, Tumor. Humans. Mice. Proteasome Endopeptidase Complex / metabolism. Transcription, Genetic. Ubiquitin-Conjugating Enzymes / metabolism


67. Handrup MM, Møller JK, Frydenberg M, Schrøder H: Placing of tunneled central venous catheters prior to induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2010 Aug;55(2):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placing of tunneled central venous catheters prior to induction chemotherapy in children with acute lymphoblastic leukemia.
  • BACKGROUND: Tunneled central venous catheters (CVCs) are inevitable in children with acute lymphoid leukemia (ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheter-Related Infections / etiology. Catheterization, Central Venous / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582964.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Hazar V, Karasu GT, Uygun V, Akcan M, Küpesiz A, Yesilipek A: Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience. J Pediatr Hematol Oncol; 2010 Nov;32(8):e317-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
  • There is limited data about the long-term treatment outcome and prognosis of childhood acute lymphoblastic leukemia (ALL) in developing countries.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930649.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol
  •  go-up   go-down


69. Lee JH, Kwon BS, Ha IS, Cheong HI, Moon KC, Ahn HS, Choi Y: Nephrotic syndrome in a child after umbilical-cord-blood transplantation. Pediatr Nephrol; 2006 Sep;21(9):1312-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 12-year-old girl who developed nephrotic syndrome 6 months after umbilical-cord-blood transplantation (UCBT) for acute lymphoblastic leukemia (L2).
  • This is a case report of nephrotic syndrome as a manifestation of chronic GVHD developed after stem-cell transplantation.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Nephrotic Syndrome / physiopathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Graft vs Host Disease / immunology. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / pharmacology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nephron. 1998 Nov;80(3):371-2 [9807057.001]
  • [Cites] Clin Nephrol. 1992 Mar;37(3):115-8 [1563114.001]
  • [Cites] Clin Nephrol. 2002 Sep;58(3):231-7 [12356194.001]
  • [Cites] Bone Marrow Transplant. 2001 Jul;28(2):121-9 [11509929.001]
  • [Cites] Am J Kidney Dis. 2005 Sep;46(3):550-6 [16129218.001]
  • [Cites] Blood. 2003 May 15;101(10):4219-21 [12543867.001]
  • [Cites] Nephrol Dial Transplant. 1999 Oct;14(10):2461-3 [10528673.001]
  • [Cites] Intern Med. 2004 Jun;43(6):512-5 [15283190.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):99-101 [10037059.001]
  • [Cites] Nephrol Dial Transplant. 2001 Feb;16(2):221-4 [11158391.001]
  • [Cites] Am J Kidney Dis. 1988 Feb;11(2):188-91 [3277409.001]
  • [Cites] Am J Kidney Dis. 2000 Sep;36(3):474-80 [10977778.001]
  • [Cites] Am J Kidney Dis. 1995 Sep;26(3):532-4 [7645565.001]
  • [Cites] Am J Med. 1975 Mar;58(3):431-7 [1078754.001]
  • [Cites] Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi26-9 [12953038.001]
  • [Cites] Kidney Int. 1980 Jan;17(1):1-13 [6990087.001]
  • [Cites] Nephrology (Carlton). 2005 Oct;10(5):530-6 [16221108.001]
  • [Cites] Nephron. 2001 Jul;88(3):260-3 [11423758.001]
  • [Cites] J Exp Med. 2002 Mar 18;195(6):665-72 [11901193.001]
  • [Cites] Histopathology. 2004 Dec;45(6):648-51 [15569061.001]
  • [Cites] Int J Hematol. 2003 Oct;78(3):262-5 [14604287.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):287-9 [12692432.001]
  • [Cites] Bone Marrow Transplant. 1995 Aug;16(2):303-5 [7581152.001]
  • [Cites] Clin Transplant. 2005 Feb;19(1):141-4 [15659148.001]
  • [Cites] Annu Rev Med. 2003;54:29-52 [12359826.001]
  • [Cites] Am J Nephrol. 2001 Sep-Oct;21(5):351-6 [11684793.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):1005-6 [15489871.001]
  • [Cites] J Exp Med. 1984 Feb 1;159(2):508-23 [6229596.001]
  • [Cites] J Korean Med Sci. 2003 Dec;18(6):901-4 [14676453.001]
  • [Cites] Nephron. 1989;51(4):555-6 [2662038.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):E3 [10873902.001]
  • [Cites] J Nephrol. 2002 Jan-Feb;15(1):79-82 [11936432.001]
  • (PMID = 16791603.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


70. Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H: DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach. Int J Oncol; 2005 Aug;27(2):547-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach.
  • Clonal T-cell receptor gamma (TCR-gamma) rearrangements are frequently used for detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16010438.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


71. Wang X, Albertioni F: Effect of clofarabine on apoptosis and DNA synthesis in human epithelial colon cancer cells. Nucleosides Nucleotides Nucleic Acids; 2010 Jun;29(4-6):414-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clofarabine, a new-generation purine nucleoside analogue, was thought to work via three mechanisms: incorporation into DNA; induction of apoptosis; and inhibition of ribonucleotide reductase, and showed significant efficacy in pediatric relapsed/refractory acute lymphoblastic leukemia (ALL) and hematologic malignancies in adults.
  • [MeSH-minor] Cell Line, Tumor. Colonic Neoplasms. HCT116 Cells. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544529.001).
  • [ISSN] 1532-2335
  • [Journal-full-title] Nucleosides, nucleotides & nucleic acids
  • [ISO-abbreviation] Nucleosides Nucleotides Nucleic Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine; 9007-49-2 / DNA
  •  go-up   go-down


72. Jain S, Kapoor G: Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine. Pediatr Blood Cancer; 2010 May;54(5):783
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
  • [MeSH-major] Antifungal Agents / adverse effects. Antineoplastic Agents, Phytogenic / adverse effects. Mucormycosis / drug therapy. Neurotoxicity Syndromes / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Triazoles / adverse effects. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205256.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Triazoles; 5J49Q6B70F / Vincristine; 6TK1G07BHZ / posaconazole
  •  go-up   go-down


73. Bölling T, Ernst I, Könemann S, Willich N: Pediatric radiation oncology in Germany: a study of availability and application. Klin Padiatr; 2008 May-Jun;220(3):178-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric radiation oncology in Germany: a study of availability and application.
  • BACKGROUND: Radiotherapy plays a pivotal role in many multimodal therapy concepts in pediatric oncology.
  • The aim of this study was to evaluate the availability and application of pediatric radiation oncology in Germany.
  • The questions regarded the structure of the departments, the number of irradiated children each year including the distribution of the different diagnoses, the number of curative treatments, inclusion in study trials, and existence of special contact persons for pediatric radiotherapy as well as technical aspects of irradiation of children.
  • Most of these children suffered from brain tumors, Hodgkin's disease and acute lymphatic leukemia (ALL).
  • CONCLUSIONS: Due to quite low patient numbers treated in most radiotherapy facilities, individual experiences in pediatric radiation oncology can be assumed to be quite limited.
  • As radiotherapy is part of multimodal therapy approaches in pediatric oncology and children treated with radiotherapy are at special risk for potential side effects, pediatric radiation oncology remains a sophisticated area.
  • [MeSH-minor] Adolescent. Brachytherapy / utilization. Brain Neoplasms / radiotherapy. Child. Child, Preschool. Germany. Hodgkin Disease / radiotherapy. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiotherapy, Conformal / utilization. Radiotherapy, Intensity-Modulated / utilization. Surveys and Questionnaires. Utilization Review / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478491.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Pei SN, Kuo CY, Ma MC, Wang MC: Mediastinal mass and malignant pleural effusion in an aleukemic case with pre-B acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Feb;31(2):139-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal mass and malignant pleural effusion in an aleukemic case with pre-B acute lymphoblastic leukemia.
  • After a bone marrow examination, we diagnosed the patient with pre-B acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194202.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Zweidler-McKay PA: Notch signaling in pediatric malignancies. Curr Oncol Rep; 2008 Nov;10(6):459-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling in pediatric malignancies.
  • Because many pediatric malignancies arise from dysregulated development, roles for Notch signaling in these cancers are to be expected.
  • Evidence to support this is now emerging as the Notch pathway is being explored in more pediatric cancers.
  • As examples, although activating mutations of Notch1 are found in the majority of T-cell acute lymphoblastic leukemia (ALL) cases, Notch/HES1 signaling appears to play a tumor suppressor role in precursor B-cell ALL; although Notch/HES1 signaling appears to contribute to osteosarcoma metastasis, Notch signaling also promotes medulloblastoma "stem cell" survival and contributes to angiogenesis in neuroblastoma.
  • Further understanding of the roles of Notch signaling in specific pediatric cancers will provide a rationale for Notch-based therapeutic strategies.
  • [MeSH-minor] Animals. Cell Lineage. Cell Survival. Child. Genes, Tumor Suppressor. Humans. Mutation. Neoplasm Metastasis. Osteosarcoma / therapy. Signal Transduction. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Jul;8(1):13-23 [16023595.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):401-10 [11054669.001]
  • [Cites] Leukemia. 2005 Feb;19(2):260-7 [15565166.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):813-9 [17551948.001]
  • [Cites] Int J Oncol. 2008 Jun;32(6):1335-41 [18497996.001]
  • [Cites] Stroke. 2008 Jan;39(1):220-6 [18063826.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(5):699-709 [18294840.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14 (10 ):2962-9 [18483362.001]
  • [Cites] Annu Rev Pathol. 2008;3:587-613 [18039126.001]
  • [Cites] Haematologica. 2008 Apr;93(4):533-42 [18322257.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):329-40 [15288258.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1686-94 [17456774.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3706-14 [17671232.001]
  • [Cites] Bioessays. 2008 Apr;30(4):303-13 [18348190.001]
  • [Cites] Br J Cancer. 2005 Feb 28;92 (4):751-9 [15685243.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2821-7 [18539960.001]
  • [Cites] Hum Mol Genet. 2007 Nov 15;16(22):2683-92 [17720887.001]
  • [Cites] Neurol Sci. 2005 Jun;26(2):117-24 [15995828.001]
  • [Cites] Cell Cycle. 2008 Apr 15;7(8):965-70 [18414037.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] J Cell Biochem. 2003 Feb 15;88(3):569-77 [12532332.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12 ):4727-35 [18559519.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 24;256(3):557-63 [10080936.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2273-7 [18528422.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1963-6 [17008890.001]
  • [Cites] Leukemia. 2004 Apr;18(4):777-87 [14961038.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jan-Feb;40(1):119-21 [17988908.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2220-9 [18039953.001]
  • [Cites] Leuk Lymphoma. 2001 Jul;42(3):467-72 [11699411.001]
  • [Cites] Immunity. 1998 Jan;8(1):43-55 [9462510.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2634-40 [18250475.001]
  • [Cites] Int J Oncol. 2003 May;22(5):1073-9 [12684674.001]
  • [Cites] Blood. 2004 May 1;103(9):3511-5 [14726396.001]
  • [Cites] Cancer Lett. 2005 Feb 28;219(1):113-20 [15694671.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3898-906 [16118316.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Am J Hum Genet. 2006 Jan;78(1):28-37 [16385447.001]
  • [Cites] Oncologist. 2007 Aug;12(8):942-51 [17766653.001]
  • [Cites] Exp Cell Res. 2008 Feb 15;314(4):707-19 [18201699.001]
  • [Cites] Endocr Rev. 2007 May;28(3):339-63 [17409286.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R9-13 [12668592.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):902-6 [16894623.001]
  • [Cites] Blood. 2004 May 1;103(9):3503-10 [14670925.001]
  • [Cites] Exp Hematol. 2005 May;33(5):558-63 [15850833.001]
  • (PMID = 18928660.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 50
  •  go-up   go-down


76. Baytan B, Ozdemir O, Gunes AM, Dönmez O: Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Mar;32(2):144-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia.
  • Clofarabine has significant efficiency in children with relapsed or refractory leukemia.
  • In previous pediatric trials, various adverse effects have been described.
  • In this case, we report a child with refractory acute lymphoblastic leukemia who developed fatal capillary leak syndrome during clofarabine therapy.
  • [MeSH-major] Adenine Nucleotides / adverse effects. Antineoplastic Agents / adverse effects. Arabinonucleosides / adverse effects. Capillary Leak Syndrome / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20057324.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


77. Pui CH: Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program; 2006;:142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment.
  • Improved treatment for acute lymphoblastic leukemia (ALL) has virtually eliminated testicular relapse.
  • However, the control of central nervous system (CNS) leukemia remains a therapeutic challenge in childhood ALL, partly because of the late complications arising from cranial irradiation.
  • In most current pediatric protocols, cranial irradiation (12 to 18 Gy) is given to 5% to 25% of patients--those with T-cell ALL, overt CNS disease (CNS3 status) or high-risk cytogenetics.
  • Children with B-cell precursor ALL who have a late CNS relapse (after an initial remission of 18 months or more) and did not receive cranial irradiation have an excellent outcome after retrieval therapy, with a 5-year event-free survival (EFS) rate approaching that in newly diagnosed patients.
  • Innovative treatment options are needed for children who develop CNS relapses after a short initial remission or after receiving cranial irradiation, and in any adults with CNS leukemia at diagnosis or relapse.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124053.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / CA-71907; United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / GM-61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


78. Cario G, Stanulla M, Fine BM, Teuffel O, Neuhoff NV, Schrauder A, Flohr T, Schäfer BW, Bartram CR, Welte K, Schlegelberger B, Schrappe M: Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood; 2005 Jan 15;105(2):821-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
  • Treatment resistance, as indicated by the presence of high levels of minimal residual disease (MRD) after induction therapy and induction consolidation, is associated with a poor prognosis in childhood acute lymphoblastic leukemia (ALL).
  • Genes with low expression in resistant samples were predominantly associated with cell-cycle progression and apoptosis, suggesting that impaired cell proliferation and apoptosis are involved in treatment resistance.
  • Because treatment response could be predicted with high accuracy, gene expression profiling could become a clinically relevant tool for treatment stratification in the early course of childhood ALL.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Gene Expression Profiling. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


79. Cowan SA: Denmark decides not to introduce hepatitis B into the childhood vaccination programme. Euro Surveill; 2005;10(11):E051103.3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denmark decides not to introduce hepatitis B into the childhood vaccination programme.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794274.001).
  • [ISSN] 1560-7917
  • [Journal-full-title] Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
  • [ISO-abbreviation] Euro Surveill.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


80. Khan NI, Cisterne A, Devidas M, Shuster J, Hunger SP, Shaw PJ, Bradstock KF, Bendall LJ: Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics. Leuk Lymphoma; 2008 Apr;49(4):710-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics.
  • Although significant progress has been made in the treatment of childhood acute lymphoblastic leukemia (ALL) the prognosis following relapse is still poor.
  • In this study, we examined CD44 and CD44v6 protein expression by flow cytometry and CD44v6 mRNA expression by quantitative RT-PCR in diagnostic samples from 97 pediatric patients with ALL.
  • [MeSH-major] Antigens, CD44 / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398738.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44v6 antigen
  •  go-up   go-down


81. Ozdemir MA, Karakukcu M, Patiroglu T, Torun YA, Kose M: Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia. Acta Haematol; 2009;121(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.
  • INTRODUCTION: The standard management of childhood acute lymphoblastic leukemia with hyperleukocytosis is unclear and its treatment has focused on prompt leukocytoreduction.
  • METHODS: In the present prospective trial, 15 children with acute lymphoblastic leukemia and hyperleukocytosis (range 101-838 x 10(9)/l) were treated with intravenous low-dose prednisone continuous infusion (6 mg/m(2)/24 h).
  • RESULTS: The mean reduction in white blood cell count achieved by this treatment was 34.4% on first day, 56.9% on second day and 76.6% on third day.
  • CONCLUSIONS: Intravenous low-dose prednisone continuous infusion treatment can prevent the progression to tumor lysis syndrome and it may be used for the patients presenting with white blood cell counts between 100 and 400 x 10(9)/l in centers where leukoapheresis is not readily available.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Leukocytosis / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / administration & dosage. Tumor Lysis Syndrome / prevention & control

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19339772.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; VB0R961HZT / Prednisone
  •  go-up   go-down


82. Faiz M, Qazi JI: t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Punjab, Pakistan. J Pediatr Hematol Oncol; 2010 Apr;32(3):249-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Punjab, Pakistan.
  • [MeSH-major] Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 21 / genetics. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics


83. Calaminus G, Hense B, Laws HJ, Groeger M, MacKenzie CR, Göbel U: Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92. Klin Padiatr; 2007 Nov-Dec;219(6):355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92.
  • BACKGROUND: Children and adolescents after acute lymphoblastic leukemia are at risk for a prolonged period of immunodeficiency.
  • [MeSH-major] Antibodies, Bacterial / blood. Diphtheria Toxoid / immunology. Immunologic Memory. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology

  • Genetic Alliance. consumer health - Diphtheria.
  • Genetic Alliance. consumer health - Tetanus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050047.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Diphtheria Toxoid; 0 / Tetanus Toxoid
  •  go-up   go-down


84. Treviño LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, Willman C, Neale G, Downing J, Raimondi SC, Pui CH, Evans WE, Relling MV: Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet; 2009 Sep;41(9):1001-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline genomic variants associated with childhood acute lymphoblastic leukemia.
  • Using the Affymetrix 500K Mapping array and publicly available genotypes, we identified 18 SNPs whose allele frequency differed significantly(P < 1 x 10(-5)) between pediatric acute lymphoblastic leukemia (ALL) cases (n = 317) and non-ALL controls (n = 17,958).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827856359 for PMID:19684603 [PharmGKB] .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2008;9(2):R38 [18291030.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] JAMA. 2008 May 28;299(20):2423-36 [18505952.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Aug;47(8):680-96 [18398821.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):1059-63 [18495205.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):125-34 [19138562.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):385-6 [19338077.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Genome Res. 2001 Aug;11(8):1327-34 [11483573.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1222-8 [10666194.001]
  • [Cites] Genetics. 2000 Jun;155(2):945-59 [10835412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] Cell Growth Differ. 2002 Mar;13(3):95-106 [11959810.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Am J Hum Genet. 2003 Jul;73(1):107-14 [12772088.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Br J Haematol. 2003 Oct;123(1):45-8 [14510941.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Biol Psychiatry. 2003 Dec 1;54(11):1265-73 [14643094.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1345-53 [14982958.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Cancer Res. 1983 Oct;43(10):4648-52 [6192907.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8292-303 [7969165.001]
  • [Cites] J Immunol. 1996 Jan 15;156(2):585-92 [8543809.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1068-73 [9353182.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):66-80 [15640446.001]
  • [Cites] BMC Med Genet. 2005 May 27;6:23 [15921520.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Oct;44(2):113-22 [15942938.001]
  • [Cites] Am J Hum Genet. 2006 Feb;78(2):315-33 [16400611.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Haematologica. 2006 Jan;91(1):139-40 [16434385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Blood. 2007 Jan 15;109(2):683-92 [17008550.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1172-7 [17548681.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Biomarkers. 2008 May;13(3):282-95 [18415801.001]
  • [Cites] Eur J Cancer Prev. 2008 Jun;17(3):251-8 [18414197.001]
  • (PMID = 19684603.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH061675; United States / NIMH NIH HHS / MH / R01 MH059556; United States / NCI NIH HHS / CA / CA021765-259006; United States / NCI NIH HHS / CA / U10 CA098413-07; None / None / / U10 CA029139-22; None / None / / U10 CA098413-07; United States / NHLBI NIH HHS / HL / U01 HL65899; United States / NCI NIH HHS / CA / CA 078224; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / CA 36401; United States / NCI NIH HHS / CA / P30 CA021765-259006; United States / NCI NIH HHS / CA / R37 CA036401-24; United States / NIMH NIH HHS / MH / U01 MH046276; United States / NIMH NIH HHS / MH / R01 MH059535; United States / NIMH NIH HHS / MH / R01 MH059567; United States / NIMH NIH HHS / MH / R01 MH059545; United States / NIGMS NIH HHS / GM / GM061374-07; United States / NCI NIH HHS / CA / CA 51001; United States / NCI NIH HHS / CA / CA078224-10; United States / NHLBI NIH HHS / HL / U01 HL065899; United States / NIMH NIH HHS / MH / U01 MH079469; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / U10 CA098413; None / None / / R01 CA051001-15; United States / NIGMS NIH HHS / GM / U01GM61374; United States / NIGMS NIH HHS / GM / GM061393-100007; United States / NIMH NIH HHS / MH / R01 MH059548; United States / NIMH NIH HHS / MH / R01 MH067257; United States / NIMH NIH HHS / MH / R01 MH060870; United States / NIMH NIH HHS / MH / R01 MH081800; United States / NIMH NIH HHS / MH / R01 MH059534; United States / NIMH NIH HHS / MH / R01 MH059571; United States / NIMH NIH HHS / MH / R01 MH059565; United States / NCI NIH HHS / CA / CA036401-24; United States / NIGMS NIH HHS / GM / U01 GM061374-07; United States / NIMH NIH HHS / MH / U01 MH079470; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NIMH NIH HHS / MH / R01 MH059587; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIMH NIH HHS / MH / R01 MH059533; United States / NIGMS NIH HHS / GM / U01 GM061374; United States / NCI NIH HHS / CA / R01 CA078224-10; United States / NIMH NIH HHS / MH / R01 MH059586; United States / NCI NIH HHS / CA / U10 CA098543; United States / NHLBI NIH HHS / HL / U01 HL065899-07; United States / NHLBI NIH HHS / HL / HL065899-07; United States / NCI NIH HHS / CA / R01 CA051001; United States / NIMH NIH HHS / MH / Z01 MH002810; United States / NCI NIH HHS / CA / R01 CA036401; United States / NIMH NIH HHS / MH / R01 MH059566; United States / NIGMS NIH HHS / GM / U01 GM061393-100007; None / None / / U10 CA098543-07; United States / NIMH NIH HHS / MH / R01 MH059588; United States / NIMH NIH HHS / MH / U01 MH046318; United States / NCI NIH HHS / CA / U10 CA098543-07; United States / NIMH NIH HHS / MH / R01 MH059553; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / U10 CA029139-22; United States / NIMH NIH HHS / MH / R01 MH060879; United States / NIMH NIH HHS / MH / R01 MH060068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARID5B protein, human; 0 / Antimetabolites, Antineoplastic; 0 / DNA-Binding Proteins; 0 / IKZF1 protein, human; 0 / MKL1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Trans-Activators; 0 / Transcription Factors; 148971-36-2 / Ikaros Transcription Factor; 25513-46-6 / Polyglutamic Acid; EC 4.1.1.- / Dopa Decarboxylase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS134891; NLM/ PMC2762391
  •  go-up   go-down


85. Riga M, Korres S, Psarommatis I, Varvutsi M, Giotakis I, Papadas T, Ferekidis E, Apostolopoulos N: Neurotoxicity of BFM-95 on the medial olivocochlear bundle assessed by means of contralateral suppression of 2f1-f2 distortion product otoacoustic emissions. Otol Neurotol; 2007 Feb;28(2):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Berlin-Frankfurt-Munster 95 (BFM-95) is a common chemotherapeutic protocol against acute lymphoblastic leukemia (ALL).
  • SETTING: Oncology and otorhinolaryngology departments in a pediatric hospital.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols. Auditory Pathways / drug effects. Hearing Loss, Sensorineural / chemically induced. Olivary Nucleus / drug effects. Olivary Nucleus / physiopathology. Otoacoustic Emissions, Spontaneous / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Vincristine / adverse effects

  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255889.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gentamicins; 5J49Q6B70F / Vincristine
  •  go-up   go-down


86. Riga M, Korres S, Varvutsi M, Kosmidis H, Douniadakis D, Psarommatis I, Yiotakis I, Ferekidis E: Long-term effects of chemotherapy for acute lymphoblastic leukemia on the medial olivocochlear bundle: effects of different cumulative doses of gentamicin. Int J Pediatr Otorhinolaryngol; 2007 Nov;71(11):1767-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of chemotherapy for acute lymphoblastic leukemia on the medial olivocochlear bundle: effects of different cumulative doses of gentamicin.
  • OBJECTIVE: The treatment of acute lymphoblastic leukemia (ALL) often combines a neurotoxic chemotherapeutic protocol such as Berlin-Frankfurt-Munster-95 (BFM-95) with gentamicin, an antibiotic known to have an early and quickly reversed impact on olivocochlear reflex in animal studies.
  • [MeSH-major] Anti-Bacterial Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cochlear Nerve / drug effects. Cochlear Nerve / physiopathology. Gentamicins / adverse effects. Hair Cells, Auditory, Inner / drug effects. Nerve Fibers / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884185.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gentamicins
  •  go-up   go-down


87. Naithani R, Rai S, Choudhry VP: Septic arthritis of hip in a neutropenic child caused by Salmonella typhi. J Pediatr Hematol Oncol; 2008 Feb;30(2):182-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 5-year-old male child was undergoing chemotherapy for pre-B acute lymphoblastic leukemia.
  • [MeSH-major] Arthritis, Infectious / etiology. Hip Joint. Neutropenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Typhoid Fever / complications

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376276.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


88. Gao YJ, Zhu XH, Yang Y, Wu Y, Lu FJ, Zhai XW, Wang HS: Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China. Cancer Genet Cytogenet; 2007 Oct 1;178(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China.
  • A series of 92 Chinese children newly diagnosed with acute lymphoblastic leukemia (ALL) were examined for the ETV6-RUNX1 (previously TEL-AML1) fusion gene by using a nested reverse transcriptase-polymerase chain reaction.
  • ETV6-RUNX1 fusion transcripts were detected in 21 of 92 patients (22.8%): 16 with common ALL, 4 with precursor B-cell ALL, and 1 with T-ALL.
  • The prevalence of ETV6-RUNX1 positivity was 24.7% (20/81) in childhood B-lineage ALL.
  • The prevalence of ETV6-RUNX1 in Chinese pediatric ALL patients proved to be similar to that found in other countries.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / biosynthesis. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / biosynthesis. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / biosynthesis. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889709.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


89. Alikasifoglu A, Yetgin S, Cetin M, Tuncer M, Gumruk F, Gurgey A, Yordam N: Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments. Am J Hematol; 2005 Oct;80(2):113-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments.
  • During recent decades, the survival rate after childhood acute lymphoblastic leukemia (ALL) has improved substantially; consequently, the long-term side effects of ALL and its treatment have gained attention, of which osteoporosis is one of the most important.
  • The purpose of the present study was to compare the influence of different treatment protocols that include high-dose methylprednisolone (HDMP) versus conventional-dose prednisolone (CDP) for remission-induction therapy on bone mineral density (BMD) and serum bone turnover markers in survivors of childhood ALL after cessation of chemotherapy.
  • [MeSH-major] Bone Density / drug effects. Bone Remodeling / drug effects. Methylprednisolone / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / adverse effects


90. Luczynski W, Kowalczuk O, Stasiak-Barmuta A, Ilendo E, Krawczuk-Rybak M, Chyczewski L: Acute lymphoblastic leukemia-derived dendritic cells express tumor associated antigens: PNPT1, PMPCB, RHAMM, BSG and ERCC1. Neoplasma; 2009;56(5):428-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia-derived dendritic cells express tumor associated antigens: PNPT1, PMPCB, RHAMM, BSG and ERCC1.
  • In all types of leukemia both in children and adults there is a need for novel therapies that could reduce the risk of relapse after standard treatment.
  • Acute lymphoblastic leukemia (ALL) cells are ineffective antigen presenting cells, but as shown by many authors including results from our laboratory, stimulation with CD40L restores their antigen expressing capacity.
  • The development of T-cell therapies for leukemic patients can be based on discovery of leukemia-associated antigens (LAA) which could be recognized by the host immune system.
  • The aim of our present study was to test the hypothesis that leukemia-derived dendritic cells maintain the expression of tumor associated antigens.
  • Twenty five children with B-cell precursor ALL were prospectively enrolled into the study.
  • [MeSH-major] Antigens, CD147 / genetics. Antigens, CD44 / genetics. Antigens, Neoplasm / genetics. DNA-Binding Proteins / genetics. Dendritic Cells / metabolism. Endonucleases / genetics. Exoribonucleases / genetics. Extracellular Matrix Proteins / genetics. Metalloendopeptidases / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19580345.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BSG protein, human; 0 / DNA-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / hyaluronan-mediated motility receptor; 136894-56-9 / Antigens, CD147; 147205-72-9 / CD40 Ligand; 207137-56-2 / Interleukin-4; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.13.- / PNPT1 protein, human; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.64 / mitochondrial processing peptidase
  •  go-up   go-down


91. Buldini B, Zangrando A, Michielotto B, Veltroni M, Giarin E, Tosato F, Cazzaniga G, Biondi A, Basso G: Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol; 2010 Feb;85(2):138-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Gene Expression Regulation, Leukemic. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095033.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


92. Todo K, Morimoto A, Osone S, Nukina S, Ohtsuka T, Ishida H, Yoshihara T, Todo S: Isolated relapse of acute lymphoblastic leukemia in the breast of a young female. Pediatr Hematol Oncol; 2008 Sep;25(6):607-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated relapse of acute lymphoblastic leukemia in the breast of a young female.
  • A 20-year-old female developed a relapse of B-precursor acute lymphoblastic leukemia (ALL) as a mass in her left breast after 6 years of maintained continuous complete remission.
  • [MeSH-major] Breast Neoplasms / secondary. Neoplasm Recurrence, Local. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728980.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Collins L, Zarzabal LA, Nayiager T, Pollock BH, Barr RD: Growth in children with acute lymphoblastic leukemia during treatment. J Pediatr Hematol Oncol; 2010 Nov;32(8):e304-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth in children with acute lymphoblastic leukemia during treatment.
  • This is especially true in children with acute lymphoblastic leukemia (ALL) in whom the metabolic syndrome may begin during therapy, demanding clarification of the trajectory of weight gain so that effective interventions may be developed.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Growth and Development / drug effects. Obesity / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Prednisolone / adverse effects. Radiotherapy / adverse effects


94. Abdelrazik N, Fouda M: Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Hematology; 2007 Dec;12(6):533-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
  • AIM OF THE STUDY: To demonstrate the effectiveness of once-weekly (QW) rHuEPO dosing to effect improved hemoglobin levels, decreased transfusion use, and improved functional outcomes and QOL in pediatric leukemic patients (ALL) receiving maintenance chemotherapy.
  • PATIENT AND METHODS: This was a prospective randomized, single-center, open-label, 12-week case-control study of epoetin alfa in pediatric patients with acute lymphoblastic leukemia (ALL) in remission receiving maintenance chemotherapy.
  • Both groups were matched as regard age, sex, baseline Hb concentration, remission state, chemotherapy regimen, numbers and amount of blood transfusion, and leukemia state (both were low and standard risk).
  • [MeSH-major] Anemia / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Erythropoietin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852440.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 64FS3BFH5W / Epoetin Alfa
  •  go-up   go-down


95. Mejía-Aranguré JM, Bonilla M, Lorenzana R, Juárez-Ocaña S, de Reyes G, Pérez-Saldivar ML, González-Miranda G, Bernáldez-Ríos R, Ortiz-Fernández A, Ortega-Alvarez M, Martínez-García Mdel C, Fajardo-Gutiérrez A: Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer; 2005;5:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There are very few studies that report the incidence of acute leukemias in children in Latin America.
  • This work assesses the incidence of acute leukemias, between 1996 and 2000, in children from 0-14 years old who were attended at the Mexican Social Security Institute in Mexico City and in children from 0-11 years old in El Salvador.
  • The Pediatric Hospital and the General Hospital of the Mexican Social Security Institute in Mexico City, the only centers in Mexico City which attend all those children with acute leukemia who have a right to this service.
  • DIAGNOSIS: All patients were diagnosed by bone marrow smear and were divided into acute lymphoid leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and unspecified leukemias (UL).
  • [MeSH-major] Leukemia / diagnosis. Leukemia / epidemiology
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. El Salvador. Hospital Records. Humans. Incidence. Infant. Infant, Newborn. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / epidemiology. Mexico. Population. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Prevalence

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Panam Salud Publica. 1999 Aug;6(2):75-88 [10574008.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1070-9 [10491536.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Nov-Dec;22(6):495-501 [11132215.001]
  • [Cites] Salud Publica Mex. 2000 Sep-Oct;42(5):431-7 [11125628.001]
  • [Cites] Curr Opin Pediatr. 2001 Feb;13(1):1-9 [11176236.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1402-8 [11283943.001]
  • [Cites] Eur J Cancer. 2001 Apr;37(6):695-702 [11311643.001]
  • [Cites] Med Pediatr Oncol. 2001 Oct;37(4):400-4 [11568906.001]
  • [Cites] Environ Health Perspect. 2002 Mar;110(3):319-24 [11882484.001]
  • [Cites] Med Pediatr Oncol. 2002 Jul;39(1):25-31 [12116075.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Jul;16(3):210-8 [12123433.001]
  • [Cites] Med Pediatr Oncol. 2002 Dec;39(6):554-7; discussion 552-3 [12376977.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1771-6 [15150603.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):1-3 [15226760.001]
  • [Cites] BMC Cancer. 2004 Aug 13;4:50 [15310396.001]
  • [Cites] Bol Med Hosp Infant Mex. 1993 Apr;50(4):248-57 [8471171.001]
  • [Cites] East Afr Med J. 1994 Apr;71(4):223-5 [8062767.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):94-100 [7749772.001]
  • [Cites] Blood. 1996 Jan 1;87(1):308-13 [8547657.001]
  • [Cites] Arch Med Res. 1996 Summer;27(2):223-7 [8696068.001]
  • [Cites] Blood. 1996 Jul 1;88(1):377 [8704198.001]
  • [Cites] Blood. 1997 Jan 1;89(1):348-9 [8978313.001]
  • [Cites] Med Pediatr Oncol. 1997 Sep;29(3):208-12 [9212846.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Blood. 2000 Jul 1;96(1):24-33 [10891426.001]
  • (PMID = 15807901.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1090561
  •  go-up   go-down


96. Mattison R, Stock W: Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep; 2008 Jul;3(3):144-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.
  • Acute lymphoblastic leukemia affects infants, children, adolescents, and adults.
  • This review describes biology, prognostic factors, and treatment approaches in adolescents and young adults with acute lymphoblastic leukemia.
  • Assessing the outcomes in adult and pediatric clinical trials that enroll adolescents and young adults can be especially useful in determining how best to treat these patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):166-73 [16029445.001]
  • [Cites] Med Pediatr Oncol. 1988;16(5):297-303 [3054451.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2364-71 [10733508.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):813-9 [17327603.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3377-85 [8490886.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2032-5 [15483674.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):37-51 [14766125.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2005 May-Jun;35(5):182-217 [15841070.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:123-30 [16304369.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2579-83 [14642920.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 1997 Jul 15;90(2):571-7 [9226156.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):254-61 [16421910.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Eur J Haematol. 2005 Jun;74(6):466-80 [15876250.001]
  • [Cites] Blood. 1993 May 1;81(9):2386-93 [8481519.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1646-54 [18502832.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):760-1 [12610169.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 20425459.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


97. Jain N, Brouwers P, Okcu MF, Cirino PT, Krull KR: Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia. Cancer; 2009 Sep 15;115(18):4238-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Neurocognitive problems are a frequent outcome of chemotherapy for pediatric leukemia, although individual differences exist in patient outcome.
  • The purpose of this study was to evaluate the pattern of attention problems in male and female long-term survivors of pediatric acute lymphoblastic leukemia (ALL).
  • CONCLUSIONS: The results of this study suggest that children diagnosed with and treated for pediatric ALL perform poorly on select measures of attention and executive control, and that this performance is influenced by sex and treatment intensity.
  • [MeSH-major] Attention. Cognition Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Sex Characteristics. Survivors / psychology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19536898.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Salzer WL, Devidas M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM, Kurtzberg J, Children's Oncology Group: Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol; 2007 Jun;29(6):369-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  • The Pediatric Oncology Group 9203 pilot protocol was designed to determine the feasibility of delivering 29 biweekly doses of polyethylene glycol (PEG)-L-asparaginase, on a backbone of intensive multiagent antimetabolite-based consolidation and maintenance in higher risk B-precursor acute lymphoblastic leukemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Polyethylene Glycols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551397.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 30969; United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / U10 CA 29139
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


99. Geenen MM, Bakker PJ, Kremer LC, Kastelein JJ, van Leeuwen FE: Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer; 2010 Oct;55(4):690-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy.
  • BACKGROUND: Only a few studies have assessed cardiovascular risk factors (CRFs) in childhood cancer survivors.
  • We determined the prevalence of CRFs in long-term survivors of acute lymphoblastic leukemia (ALL) and Wilms tumor.
  • [MeSH-major] Cardiovascular Diseases / etiology. Kidney Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20589650.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


100. Al-Mohammed HI, Mahyoub FH, Moftah BA: Comparative study on skin dose measurement using MOSFET and TLD for pediatric patients with acute lymphatic leukemia. Med Sci Monit; 2010 Jul;16(7):CR325-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study on skin dose measurement using MOSFET and TLD for pediatric patients with acute lymphatic leukemia.
  • BACKGROUND: The object of this study was to compare the difference of skin dose measured in patients with acute lymphatic leukemia (ALL) treated with total body irradiation (TBI) using metal oxide semiconductor field-effect transistors (mobile MOSFET dose verification system (TN-RD-70-W) and thermoluminescent dosimeters (TLD-100 chips, Harshaw/ Bicron, OH, USA).
  • MATERIAL/METHODS: The measurements involved 10 pediatric patients ages between 3 and 14 years.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Semiconductors. Skin / radiation effects. Thermoluminescent Dosimetry / methods. Transistors, Electronic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581774.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down






Advertisement